Protocol Addendum J2G-MC-JZPB (a) 
A Phase 1, Open-Label, 
Drug Interaction Study to Investigate the Effect of Single Dose 
Selpercatinib on the Pharmacokinetics of Rosuvastatin in Healthy Participants
[STUDY_ID_REMOVED] 
Approval Date: 19-M ay
-2023
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 1 Title Page   
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clin ical 
investigation of selpercatinib  (LY3527723 ) unless  such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries.  
 
Note to Regulatory Authorities:  This document may contain protected personal data and/or commerci ally confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
 
Protocol Title:   
A Phase 1 , Open-Label, Drug Interaction Study to Investigate  the Effect of Single Dose 
Selpercatinib  on the Pharmacokinetics of Rosuvastatin in Healthy  Participants  
Protocol Number:  J2G-MC-JZPB  
Amendment Number: a  
Compound : LY3527723  (selpercatinib ) 
Brief Title:  
A drug interaction study to investigate the effect of selpercatinib on the pharmacokinetics of 
rosuvastatin . 
Study Phase: Phase 1 
Acronym : JZPB  
Sponsor Name:  Eli Lilly and Company  
Legal Registered Address:  Eli Lilly and Company, Indianapolis, Indiana USA 46285  
Regulatory Agency Identifier Number : 
IND: 133193  
Approval Date:  Protocol  Amendment  (a) Electronically  Signed and  Approved  by Lilly  on date 
provided below.   
Document ID:  VV-CLIN -116682  
  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 2 Medical Monitor Name and Contact Information will be provided separately . 
 
  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 3 Protocol Amendment Summa ry of Changes Table   
 
DOCUMENT HISTORY  
Document  Date  
Original Protocol  03-Apr-2023  
Amendment [a]  
Overall Rationale for the Amendment:  
The protocol is being amended to remove language specific to case report form  entry.  
 
Section # and Name  Description of Change  Brief Rationale  
Section 8  
Study Assessments 
and Procedures  Removed  bullet  5. To remove language regarding sample 
collection actual time case report form 
(CRF ) entry for consistency with the 
study electronic case report form ( eCRF ) 
build.  
 
  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 4 Table of Contents   
1. Protocol Summary  ................................ ................................ ................................ .......... 7 
1.1. Synopsis  ................................ ................................ ................................ ............................ 7 
1.2. Schema  ................................ ................................ ................................ .............................. 9 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 10 
2. Introduction  ................................ ................................ ................................ ................... 12 
2.1. Study Rationale  ................................ ................................ ................................ ............... 12 
2.2. Background  ................................ ................................ ................................ ..................... 12 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 13 
3. Objectives and Endpoints  ................................ ................................ ............................ 14 
4. Study Design  ................................ ................................ ................................ .................. 15 
4.1. Overall  Design  ................................ ................................ ................................ ................ 15 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 15 
4.3. Justification for Dose  ................................ ................................ ................................ ......16 
4.4. End of Study Definition  ................................ ................................ ................................ ..16 
5. Study Population  ................................ ................................ ................................ ........... 17 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 17 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 18 
5.2.1.  Rationale for Exclusion of Certain Study Participants  ................................ ................... 20 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .21 
5.3.1.  Meals and Dietary Restrictions  ................................ ................................ ....................... 21 
5.3.2.  Substance Use: Caffeine, Alcohol, and Tobacco  ................................ ............................ 21 
5.3.3.  Activity  ................................ ................................ ................................ ........................... 21 
5.4. Screen Failures  ................................ ................................ ................................ ................ 21 
5.5. Criteria for Temporarily Delaying 
Enrollment/Randomization/Administration of Study Intervention 
of a Participant  ................................ ................................ ................................ ................ 21 
6. Study Intervention(s) and Concomitant Therapy  ................................ ..................... 22 
6.1. Study Interventions Administered  ................................ ................................ .................. 22 
6.1.1.  Administration Details  ................................ ................................ ................................ ....22 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ...................... 23 
6.3. Assignment to Study Intervention  ................................ ................................ .................. 23 
6.4. Blinding  ................................ ................................ ................................ .......................... 23 
6.5. Study Intervention Compliance  ................................ ................................ ...................... 23 
6.6. Dose Modification  ................................ ................................ ................................ .......... 23 
6.7. Continued Access to Study Intervention after the End of the 
Study  ................................ ................................ ................................ ............................... 23 
6.8. Treatment of Overdose  ................................ ................................ ................................ ...24 
6.9. Prior and Concomitant Therapy  ................................ ................................ ...................... 24 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 25 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 25 
7.1.1.  Liver Chemistry Stopping Criteria  ................................ ................................ .................. 26 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 5 7.1.2.  QTc Stopping Criteria  ................................ ................................ ................................ .....26 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ 27 
7.3. Lost to Follow up  ................................ ................................ ................................ ............ 27 
8. Study Assessments and Procedures ................................ ................................ ............. 28 
8.1. Efficacy Assessments  ................................ ................................ ................................ .....28 
8.2. Safety Assessments  ................................ ................................ ................................ ......... 28 
8.2.1.  Physical Examinations  ................................ ................................ ................................ ....28 
8.2.2.  Vital Signs  ................................ ................................ ................................ ....................... 28 
8.2.3.  Electrocardiograms  ................................ ................................ ................................ ......... 29 
8.2.4.  Clinical Safety Laboratory Tests  ................................ ................................ .................... 29 
8.2.5.  Pregnancy Testing  ................................ ................................ ................................ ........... 30 
8.2.6.  Safety Monitoring  ................................ ................................ ................................ ........... 30 
8.3. Adverse Events, Serious Adverse Events, and Product 
Complaints  ................................ ................................ ................................ ...................... 34 
8.3.1.  Timing and Mechanism for Collecting Events  ................................ ............................... 35 
8.3.2.  Pregnancy  ................................ ................................ ................................ ........................ 36 
8.4. Pharmacokinetics  ................................ ................................ ................................ ............ 37 
8.4.1.  Bioanalysis  ................................ ................................ ................................ ...................... 38 
8.5. Pharmacodynamics  ................................ ................................ ................................ ......... 38 
8.6. Genetics  ................................ ................................ ................................ .......................... 38 
8.7. Biomarkers  ................................ ................................ ................................ ...................... 38 
8.8. Immunogenicity Assessments ................................ ................................ ......................... 38 
8.9. Health Economics  ................................ ................................ ................................ ........... 38 
9. Statistical Considerations  ................................ ................................ ............................. 39 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....39 
9.2. Analyses Sets  ................................ ................................ ................................ .................. 39 
9.2.1.  Study Participant Disposition  ................................ ................................ ......................... 39 
9.2.2.  Study Participant Characteristics  ................................ ................................ .................... 39 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 39 
9.3.1. General Considerations  ................................ ................................ ................................ ...40 
9.3.2.  Primary Endpoint Analysis: Pharmacokinetic Analyses  ................................ ................ 40 
9.3.3.  Secondary Endpoint Analysis: Safety Analyses  ................................ ............................. 40 
9.3.4.  Exploratory Endpoint Analysis  ................................ ................................ ....................... 41 
9.4. Interim Analysis  ................................ ................................ ................................ .............. 41 
9.5. Sample Size Determination  ................................ ................................ ............................ 42 
10. Supporting Documentation and Operational Considerations  ................................ ..43 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 43 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 43 
10.1.2.  Financial Disclosure ................................ ................................ ................................ ........ 44 
10.1.3.  Informed Consent Process  ................................ ................................ .............................. 44 
10.1.4.  Data Protection ................................ ................................ ................................ ................ 44 
10.1.5.  Dissemination of Clinical Study Data ................................ ................................ ............. 45 
10.1.6.  Data Quality Assurance  ................................ ................................ ................................ ..45 
10.1.7.  Source Documents  ................................ ................................ ................................ .......... 47 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 6 10.1.8.  Study and Site Start and Closure  ................................ ................................ .................... 47 
10.1.9.  Publication Policy  ................................ ................................ ................................ ........... 48 
10.1.10.  Investigator Information  ................................ ................................ ................................ .48 
10.1.11.  Sample Retention  ................................ ................................ ................................ ............ 48 
10.2. Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 49 
10.2.1.  Blood Sampling Summary  ................................ ................................ .............................. 51 
10.3.  Appendix 3: Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting  ................................ ................................ ................................ ............ 52 
10.3.1.  Definition of SAE  ................................ ................................ ................................ ........... 53 
10.3.2.  Definition of Product Complaints  ................................ ................................ ................... 54 
10.3.3.  Recording and Follow -Up of AE and/or SAE and Product 
Complaints  ................................ ................................ ................................ ...................... 54 
10.3.4.  Reporting of SAEs  ................................ ................................ ................................ .......... 56 
10.3.5.  Regulatory Reporting Requirements  ................................ ................................ ............... 57 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ .......................... 58 
10.4.1.  Definitions ................................ ................................ ................................ ....................... 58 
10.4.2.  Contraception Guidance ................................ ................................ ................................ ..58 
10.4.3.  Contraception Methods  ................................ ................................ ................................ ...60 
10.5.  Appendix 5: Genetics ................................ ................................ ................................ ......61 
10.6.  Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................... 62 
10.7.  Appendix 7: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  ................................ ................................ ............................. 63 
10.8.  Appendix 8: Abbreviations and Definitions  ................................ ................................ ...64 
11. References  ................................ ................................ ................................ ...................... 67 
 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 7 1. Protocol Summary   
1.1. Synopsis   
Protocol Title:   
A Phase 1, Open -Label, Drug Interaction Study to Investigate the Effect of Single Dose 
Selpercatinib on the Pharmacokinetics of Rosuvastatin in Healthy Particip ants 
Brief Title:   
A drug interaction study to investigate the effect of selpercatinib on the pharmacokinetics of 
rosuvastatin.  
Regulatory Agency Identifier Number:   
IND: 133193  
Rationale : 
Rosuvastatin is a commonly used index substrate for  breast cancer resistance protein ( BCRP ) 
(FDA, 2021). Selpercatinib may potentially inhibit BCRP in the intestine according to in vitro 
evaluation . Therefore, t his study  aims to investigate a potential drug -drug interaction (DDI) by 
evaluating the pharmacokinetics (PK), safety, and tolerability of rosuvastatin in the presence of 
selpercatinib.    
Objectives  and Endpoint s:  
Objectives  Endpoints  
Primary   
 To evaluate the effect of a single dose 
of selpercatinib on BCRP activity in 
healthy participants   Cmax and AUC (0-∞) of rosuvastatin  
Secondary   
 To describe  the safety and tolerability 
of rosuvastatin in combination with 
selpercatinib in healthy participants   Incidence of TEAEs and SAEs  
Abbreviations: AUC (0-∞) = area under the concentration versus time curve from time zero to infinity; BCRP  = breast 
cancer resistance protein; C max = maximum observed drug concentration; SAE = serious adverse event; 
TEAE  = treatment -emergent adverse event.  
 
Overall Design : 
Study J2G -MC-JZPB is a Phase 1, open -label, fixed -sequence, drug interaction study to 
investigate the effect of a single dose of selpercatinib on the PK of rosuvastatin in healthy 
participants.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 8 Brief Summary:  
The purpose of this study is to investigate a potential DDI by measur ing PK of rosuvastatin  with 
selpercatinib  in healthy participants .   
Study details include:  
● The study duration will be approximately 8  weeks.  
● The s tudy intervention will be administered on Days 1 and 5 . 
● The visit frequency will be 9 continuous days in the clinical research unit ( CRU ). 
Study Population:  
Healthy parti cipants will be enrolled in this study.    
Number of Participant s: 
Approximately 28 participants will be enrolled to ensure that a least  20 evaluable participants 
complete the study . 
Intervention Groups  and Duration : 
All participants will be screened for inclusion within 42 days prior to enrollment. Eligible 
participants will be admitted to the CRU on Day -1 and remain resident in the CRU until 
discharge on Day  8. A follow -up visit will be performed 7  to 10  days (Days  12 to 15) after the 
final dose o f study intervention.  
Participants  will receive the following study intervention while resident in the CRU : 
 Day 1: 20 mg rosuvastatin alone  
 Day 5: 20 mg rosuvastatin coadministered  simultaneously with 160 mg selpercatinib  
Ethical Considerations of Benefit/Risk:  
The following are the risk s and discomforts associated with selpercatinib:  dry mouth, diarrhea, 
hypertension, fatigue, constipation, alanine aminotransferase (ALT)/ aspartate aminotransferase 
(AST ) elevation, headache, nausea, edema peripheral, abdominal pain, rash, electrocardiogram  
QT prolonged, cough, vomiting, dyspnea, and increased blood creatinine . 
Adverse events of special interest include hypersensitivity, liver injur y, QT prolongation , and 
hypertension.  Therefore, these  reactions  will be monitored  during the course of the study . 
The following are the risks and discomforts associated with rosuvastatin:  headache , myalgia , 
abdominal pain , asthenia, nausea , ALT/AST elevation , myopathy, and rhabdomyolysis.  
Data Monitoring Committee: No 
 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 9 1.2. Schema   
 
 
 
 
 
Day -1
Follow -Up Visit
(7 to 10 days after last dose)1 2 3 4 5 6 7Rosuvastatin 20 mgRosuvastatin 20 mg
+
Selpercatinib 160 mg
12
Resident in CRU-42
Screening
Abbreviation: CRU = clinical research unit-2 15 8
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 10 1.3. Schedule of Activities  (SoA)   
Study Procedure  Screening  Treatment  FU/ED  Comments  
Study Day  -42 to -2 -1 1 2 3 4 5 6 7 8 12 to 15   
Informed consent  X            
Medical history and 
demographics  X X           
Admission to CRU   X           
Discharge from CRU           X   
Outpatient visit  X          X  
Participant eligibility  X X           
Height and weight  X X         X Height : 
screening only.  
Physical examination   X        X  Day -1: Full 
examination. 
Day 8: 
Symptom -driven 
examination.  
Pregnancy test  X X         X Serum 
pregnancy test : 
screening.  
Urine pregnancy 
test: all other 
time points.  
FSH X           See 
Section  10.4.1.  
Serology  X            
Clinical laboratory 
tests X X   X  P  X  X  
12-lead ECG (hr) X  P    P, 2, 4 24 48 72 X  
Vital signs and body 
temperature (supine) 
(hr) X X P 24 X X P, 1, 2  24 X X X Temperature :  
screening and 
Day -1. 
Ethanol test  X X           
Urine drug screen  X X           
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 11 Study Procedure  Screening  Treatment  FU/ED  Comments  
Study Day  -42 to -2 -1 1 2 3 4 5 6 7 8 12 to 15   
Genetic blood sample 
for screening  X            
Pharmacogenetic 
blood sample for 
storage    P          
Rosuvastatin 
administration    X    X      
Selpercatinib 
administration        X      
Rosuvastatin PK 
samples (hr)  
Selpercatinib PK 
samples (hr)  
Plasma 
coproporphyrin I 
samples (hr)  
Adverse events    X X X X X X X X X  
Concomitant 
medications  X X X X X X X X X X X  
Abbreviations: CRU = clinical research unit; ECG = electrocardiogram; ED = early discontinuation; FSH = follicle stimulating hormone; FU = follow -up; 
hr = hour; P = predose; PK  = pharmacokinetics .
Approved on 19 May 2023 GMT
CCI
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 12 2. Introduction   
2.1. Study Rationale   
The breast cancer resistance protei n (BCRP) is a membrane -bound transporter located in the 
gastrointestinal tract, liver, kidney, brain endothelium, mammary tissue, testis, and placenta, 
responsible for exporting a wide range of substrates across biological membranes. Certain 
substrates of BCRP have been shown to have clinically significant drug interactions when 
administered with inhibitors of BCRP (International Transporter Consortium et al. 2010).  
Rosuvastatin is a commonly used index substrate for BCRP (FDA, 2021).  Selpercatinib may 
potentially inhibit BCRP in the intestine according to in vitro  evaluation . Therefore, this study 
aims to investigate a potential drug -drug interaction (DDI) by evaluating the pharmacokinetics 
(PK), safety, and tolerability of rosuvastatin in the presence of selpercatinib.  
2.2. Background   
Selpercatinib  (LY3527723 , Retevmo ®) is a an orally available, highly selective, adenosine 
triphosphate (ATP) -competitive small molecule inhibitor of the REarranged during Transfection 
(RET)  gene receptor tyrosine kinase (RTK ) approved by the FDA  for the treatment of  
 adult patients with locally advanced or metastatic non -small cell lung cancer (NSCLC) with a 
RET gene fusion, as detected by an FDA -approved test  
 adult and pediatric patients 12  years of age and older  with advanc ed or metastatic medullary 
thyroid cancer (MTC) with a RET mutation, as detected by an FDA -approved test, who 
require systemic therapy  
 adult and pediatric patients 12  years of age and older with advanced or metastatic thyroid 
cancer with a RET gene fusion, as detected by an FDA -approved test, who require systemic 
therapy and who are radioactive iodine -refractory (if radioactive iodine is appropriate)   
 adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that 
have progressed on or following prior systemic treatment or who have no satisfactory 
alternative treatment options  
Across clinical studies, single oral doses of selpercatinib were administered over a range of 20 to 
720 mg. In studies (LOXO -RET -18017 and LOXO -RET -18026), multiple oral doses of  
160 mg/day selpercatinib were administered orally twice daily for 10  days in healthy  
participants.  
In healthy participants , the median (range)  time to maximum drug concentration  (tmax) of 
selpercatinib is 2  (1.5 to 6.0) hours and selpercatinib is eliminated with a mean (range)  terminal 
elimination half -life (t1/2) of 13.6  (9.82  to 19.6)  hours . 
More detailed information about the PK and absorption, distribution, metabolism, and excretion  
properties of selpercatinib may be found in the Investigator’s Brochure  (IB). 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 13 2.3. Benefit/Risk Assessment   
There is no anticipated therapeutic benefit for the participants in this stu dy. However,  
participants may benefit from the screening procedures (through detection of unknown health  
issues) even if they receive no therapeutic benefit from the study.  
The single dose of selpercatinib to be given in this study is 160  mg (2 × 80-mg capsules ), as it is 
the highest approved dose by the FDA . The safety profile of selpercatinib shows that 
selpercatinib is very well tolerated in healthy participants and  is clinically manageable, with low 
rates of study drug discontinuation due to adverse events ( AEs). As outlined in  the IB, the most 
common toxicities associated with selpercatinib are monitorable and reversible,  and include dry 
mouth, diarrhea, hypertension, fatigue, constipation, aspartate aminotransferase ( AST )/ alanine 
aminotransferase ( ALT ) elevation,  headache, nausea, edema peripheral, abdominal pain, rash, 
electrocardiogram ( ECG ) QT prolonged, cough, vomiting,  dyspnea , and increased blood 
creatinine. Adverse e vents of special interest include hypersensitivity,  liver injury , QT 
prolonga tion, and hypertension. In a recently completed DDI study  with dabigatran in healthy 
participants ( Study  J2G-MC-JZJV), only 1  treatment -emergent adverse event ( TEAE ) considered 
to be related to selpercatinib  was reported (dyspepsia).  In a single 160-mg dose, crossover  
bioequivalent study in 224  healthy participants (Study  J2G-MC-JZJZ), the most frequently 
reported TEAEs following dosing was headache (20 events in 16  participants) followed by 
COVID -19 (13  events in 13  participants). Four  AEs of ALT increased  and 2  AEs of AST 
increased were reported, all were mild in severity  and resolved by the end of the  study.  
More detailed information about the known and expected benefits and risks and reasonably 
expected  AEs of selpercatinib  may be found in the IB. 
Rosuvastatin is a commonly used drug in DDI studies and the dosing regimen in the current 
study (20  mg) is consistent with the prescribing recommendations. The most frequent (≥2%) 
adverse reactions following rosuvastatin dosing are headache, myalgia, a bdominal pain, asthenia, 
and nausea. Cases of myopathy and rhabdomyolysis have been reported with rosuvastatin. These 
risks can occur at any dose level, but are increased at the highest dose of 40  mg. The incidence of 
rhabdomyolysis is 0.3 to 13.5  cases pe r 1,000,000 (Mendes et al. 2014). During the current 
study, participants should promptly report any unexplained muscle pain, tenderness, or 
weakness. Elevations in liver enzymes (ALT and AST) have been reported following 
rosuvastatin dosing. In most cases,  the elevations were transient and resolved or improved on 
continued dosing or after brief  interruption of dosing. In the current study, blood samples to 
determine liver enzymes (as part of  clinical laboratory tests) will be collected prior to each 
dosing occasion of rosuvastatin.   
More detailed information about the known and expected benefits and risk and reasonably 
expected AEs of rosuvastatin may  be found in the prescribing information (Crestor ® Prescribing 
Information, 2020).  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 14 3. Objectives  and Endpoints   
Objectives  Endpoints  
Primary   
 To evaluate the effect of a single dose 
of selpercatinib on BCRP activity in 
healthy participants   Cmax and AUC (0-∞) of rosuvastatin  
Secondary   
 To describe  the safety and tolerability 
of rosuvastatin in combination with 
selpercatinib in healthy participants   Incidence of TEAEs and SAEs  
Exploratory   
 To assess  the exploratory 
measurement of plasma 
coproporphyrin  I as biomarker of 
transporter OATP 1B1 and OATP1B3  
inhibition in healthy participants to 
further inform degree of transporter 
inhibition risk   Plasma concentrations of biomarker  
coproporphyrin I: Cmax and 
AUC (0-24)  
Abbreviations: AUC (0-∞) = area under the concentration versus time curve from time zero to infinity; 
AUC (0-24) =area under the concentration versus time curve from time zero to 24 hours ; BCRP  = breast cancer 
resistance protein; C max = maximum observed drug concentration; OATP  = organic anion transporting 
polypeptide ; SAE = serious adverse event; TEAE  = treatment -emergent adverse event.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 15 4. Study Design   
4.1. Overall  Design   
Study  J2G-MC-JZPB is a Phase 1, open-label, fixed -sequence, drug interaction study to 
investigate the effect of a single dose of selpercatinib on the PK of rosuvastatin in healthy 
participants . 
The schema in Section  1.2 illustrates the study design.  
Approximately  28 participants will be enrolled to ensure that at least 20 evaluable participants 
complete the study.  
Screening  
All participants will be screened for study inclusion within 42  days prior to enrollment (Day  1). 
Screening should not occur less than 14  days prior to enrollment (Day  1) in order to allow 
sufficient time to receive genotyping results.  
Treatment and Assessment Period  
Participants will check in to the clinical research unit (CRU) on Day -1 and remain resident until 
discharge on Day  8. 
While resident at the CRU, all participants will receive study interv ention as follows:  
 Day 1: 20  mg rosuvastatin alone  
 Day 5: 20 mg rosuvastatin coadministered simultaneously with 160 mg selpercatinib  
Pharmacokinetic blood sampling and safety assessments, including vital signs measurements, 
physical examinations, clinical laboratory tests, ECGs, and AE recording, will be performed 
according to the Schedule of Activities (SoA; Section  1.3) 
Participants will be dischar ged from the CRU on Day  8 following completion of study 
procedures, provided they are deemed medically fit by the investigator or designee.  
Follow -up 
Participants will attend an outpatient follow -up visit 7  to 10  days (Days  12 to 15) after the final 
dose of rosuvastatin coadministered with a single dose of selpercatinib . If participants are not 
able to attend the CRU for this visit, the CRU should contact the participant via phone call to 
conduct AE and concomitant medication review.  
4.2. Scientific Rationale for Study Design   
To allow each participant  to act as their own control for safety and PK comparisons, a fixed  
sequence design has been selected.  This study wi ll be open label as the study primary endpoint 
PK measures are objective rather  than subject ive. 
Based on the t 1/2 of rosuvastatin from label  (19 hours; Crestor Prescribing Information, 2020 ) or 
observed from  Study  J2N-MC-JZNW  (geometric mean of 8.21 hours  with range of 3.02  to 
39.8 hours), a period of  4 days between rosuvastatin doses is considered sufficient time for the 
study intervention to  washout.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 16 The PK of rosuvastatin will be evaluated after a single dose on Day  1 and again on Day  5, 
coadministered simultaneously with selpercatinib , to assess the  effect of selpercatinib  on 
intestinal BCRP . 
Conducting the study in healthy participants mitigates the potential confounding effects of any 
disease state, other medical conditions, and concomitant medication s in patients.   
4.3. Justification for Dose   
The single  dose of 160  mg is the highest approved dose for selpercatinib.  
The dos e of rosuvastatin (20  mg) has been chosen as this is the c linically relevant dose 
considered safe to administer and has been used concomitantly in previous clinical DDI studies.  
4.4. End of Study  Definition   
The end of the study is defined as the last scheduled procedure shown in the SoA (Section  1.3) 
for the last participant in the study . 
A participant  is considered to have completed the study if the participant  has completed the 
treatment  period  of the study and the follow -up procedures as shown  in the SoA (Section  1.3). 
 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 17 5. Study Population   
Eligibility of participants for enrollment in the study will be based on the results of the h uman 
BCRP transporter  (also known as ABCG2 ) and the human organic anion transporting 
polypeptide 1B1  (OATP1B1 ) transporter  (also known as SLCO1B1 ) genotyping , screening 
medical history, physical examination, vital signs, clinical laboratory tests , and ECG. The nature 
of any conditions present at the time of the physical examination and any preexisting conditions 
will be documented.  
The inclusion and exclusion criteria used to determine eligibility should be applied at screening 
only unless otherwi se specified, and not continuously throughout the trial.  Clinical laboratory 
tests and vital signs may be repeated from screening through Day -1 at the discretion of the 
investigator in order to confirm eligibility.  
Screening may occur up to 42 days prior to enrollment  (Day  1). Participants who are not enrolled 
within 42 days of screening may undergo an additional medical assessment and/or clinical 
measurements to confirm their eligibility. In such instances, repeat the following screening tests 
and procedu res: body weight, vital signs, clinical laboratory tests,  ECG,  and pregnancy test 
(females only) . 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria   
Participants are eligible to be included in the study only if all of the following criteria apply:   
Age 
1. Participant must be 18 to 65 years of age inclusive, at the time of signing the informed 
consent.  
Race  
2. Participant must be Caucasian.  
Type of Participant and Disease Characteristics  
3. Participants who are overtly healthy as determined by medical evaluation including 
medical history, physical examination, vital signs, and ECGs . 
4. Participants who have clinical laboratory test results within the normal reference range for 
the population or investigative site, or results with acceptable deviations that are judged to 
be not clinically significant by the investigator.  
5. Participant s who have venous access sufficient to allow for blood sampling as per the 
protocol.  
Weight  
6. Body mass index within the range 19.0 to 32.0 kg/m2 (inclusive).  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 18 Sex and Contraceptive/Barrier Requirements  
7.  Male and/or female  
Contraceptive use by participants  should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studies.  For the contraception 
requirements of this protocol, see Appendix  4, Section  10.4. 
Informed Consent  
8. Capable of giving signed informed consent as described in Appendix 1  (Section  10.1), 
which includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol . 
Other Inclusion Criteria  
9. Are reliable and willing to make th emselves available for the duration of the study and are 
willing to follow study procedures.  
5.2. Exclusion Criteria   
Participants are excluded from the study if any of the following c riteria apply:    
Medical Conditions  
10. Have known allergies to selpercatinib -related compounds or any components of the 
formulation of selpercatinib, or history of significant atopy .  
11. Have a known allerg y, intolerance, or hypersensitivity  to any component of rosuvastatin  
that would pose an unacceptable risk to the participant . 
12. Have a significant history of allergic reactions to medications or food products .  
13. Have a clinically significant abnormal blood pressure and/or pulse rate as determined by 
the investigat or.  
14. Have a 12 -lead ECG abnormality that, in the opinion of the investigator,  
 increases the risks associated with participating in the study  
 a QT interval corrected using Fridericia’s formula (QTcF)  
o  >450 msec for males or  
o  >470 msec for females  
If an ECG parameter is out of range in the screening ECG, the site may perform 
2 repeat ECGs and average the 3 results to assess eligibility.  
15. Have clinically significant active cardiovascular disease or history of myocardial 
infarction within 6 months prior to the p lanned start of dosing .  
16. Have a significant previous or current history or presence of cardiovascular, respiratory, 
renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of 
significantly altering the absorption, metabolism, o r elimination of drugs; of constituting a 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 19 risk when taking the investigational product; or of interfering with the interpretation of 
data. NOTE : history of uncomplicated appendectomy is  considered  acceptable . 
17. Show a history of central nervous system condit ions such as strokes, transient ischemic 
attacks, significant head trauma, seizures, central nervous system infections, migraine, 
brain surgery, or any other neurological conditions that, in the opinion of the investigator, 
increase the risk of participati ng in the study . 
18. Have a history or presence of neuropsychiatric disease (e.g., bipolar disorder, 
schizophrenia, depression) considered as clinically significant by the investigator .  
19. Have had lymphoma, leukemia, or any malignancy within the past 5 years except for basal 
cell or squamous epithelial carcinomas of the skin that have been resected with no 
evidence of metastatic disease for 3 years . 
20. Have any medical conditions, medical history, or are taking any medications which are 
contraindicated in the sel percatinib or rosuvastatin label . 
21. Are lactating.  
Prior/Concomitant Therapy  
22. Vaccination with live vaccines within 28 days prior to screening or plans to receive such 
vaccines during the study. N OTE : use of non -live (inactivated) vaccinations will be 
allowed . 
23. Have used or a re intending to use over -the-counter or prescription medication, including 
dietary supplements  and herbal medications , within 14 days prior to dosing and until study 
discharge (apart from occasional acetaminophen (≤ 3 g/24 hours), hormonal c ontraception, 
or hormone replacement therapy) . 
Prior/Concurrent Clinical Study Experience  
24. Are currently enrolled in any other clinical study involving an investigational product or 
any other type of medical research judged not to be scientifically or medically compatible 
with this stud y. 
25. Have participated, within the last 30 days of admission, in a clinical study involving an 
investigational product. If the previous investigational product has a long half -life, 
5 half-lives or 30 days (whichever is longer) should have passed.  
26. Have previously completed or withdrawn from this study or any other study investigating 
selpercatinib .  
Diagnostic Assessments  
27. Show evidence of human immunodeficiency virus infection and/or positi ve human 
immunodeficiency virus antibodies.  
28. Have a positive HCV Ab test.  
 Participants who have spontaneously cleared HCV infection (positive HCV Ab in 
conjunction with a negative HCV RNA test at screening, in addition to no history of 
HCV antibody (anti -HCV) treatment) may be included in the study . 
29. Have a current infection with hepatitis B virus ( HBV ), that is, positive for hepatitis B 
surface antigen , polymerase chain reaction positive for HBV DNA or both.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 20 Other Exclusion Criteria  
30. Have c.34AA, c.421AA, or c.34GA/421CA genotypes of ABCG2 as determined through 
genotyping.  
31. Have c.521TC and c/521CC genotypes of SLCO1B1 as determined by genotyping . 
32. Have a positive pregnancy test at screening or Day  -1, where applicable.  
33. Are pregnant or  intend to become pregnant or to breastfeed during the  study . 
34. Regularly use known drugs of abuse or show positive findings on drug screening.  
35. Currently use or show evidence of substance abuse (including alcohol abuse) or 
dependence within the past 6 month s based on medical history at screening visit.  
36. Have donated blood of more than 500 mL within the previous 2  months of study 
screening.  
37. Have an average weekly alcohol intake that exceeds 21  units per week (males ≤65  years 
old) and 14  units per week (females) . 
38. Are unwilling to stop alcohol consumption 48  hours prior to admission to the CRU, and 
while resident at the CRU. At all other times, participants must agree to consume no more 
than 2  units per day . 
39. Smoke more than 10  cigarettes or e -cigarettes, or 3 cigars or 3  pipes, per day or are unable 
to abide by investigative site smoking restrictions . 
40. Unwilling to  limit caffeine consumption to 2 servings per day during each dosing session . 
41. Are investigator site personnel directly affiliated with this study  and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological or legally adopted.  
42. Are Lilly employees or are an employee of any third -party involved in the study who 
require exclusion of their empl oyees . 
43. In the opinion of the investigator  or sponsor, are unsuitable for inclusion in the study . 
5.2.1.  Rationale for Exclusion of Certain Study Participants   
Human BCRP , which is encoded by the gene ABCG2 , is polymorphic. Participants with the  
c.34AA, c.421AA, and c.34GA/421CA genotypes will be excluded because these genetic  
polymorphisms are associated with impaired BCRP activity (Furukawa et al. 2009, Wan et al.  
2015, Keskitalo et al. 2009). Because the activity of BCRP is impaired with these participants, it  
would be anticipated that even complete inhibition of BCRP would not result in a substantial  
change in rosuvastatin exposure. Accordingly, excluding participants w ith these polymorphisms  
will ensure that the “worst -case” interaction between selpercatinib and rosuvastatin will be  
evaluated in this study.  
To reduce the number of participants  who need to be screened for the study, participation is 
limited to Caucasian s because c.421C >A and c.34G >A polymorphisms  occur at lower 
frequencies in Caucasians ( Kim et al, 2010 ). 
Human OATP1B1 transporter , which is encoded by the gene SLCO1B1 , is also polymorphic. To 
minimize variability in  rosuvastatin  PK, participants with the  c.521TC and c/521CC genotypes 
will be excluded from this study because this genetic  polymorphism is associated with decreased 
transporting activity of OATP1B1 (Niemi et al.  2011) and higher plasma rosuvastatin 
concentrations (Crestor Prescribing Informatio n, 2020).  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 21 5.3. Lifestyle Considerations   
Throughout the study, participants may undergo medical assessments and review of compliance 
with requirements before continuing in the study.  
5.3.1.  Meals and Dietary Restrictions   
 Standard meals will be provided at all times while participants are resident at the CRU, 
as per the CRU’s policy.  
5.3.2.  Substance Use: Caffeine, Alcohol,  and Tobacco   
 During each do se administ ration , participants will be allowed to ingest 2  servings per 
day of caffeine or xanthine containing products.   
 Participant s will abstain f rom alcohol for 48 hours prior to admission until discharge 
from the CRU . 
 Participant s who use tobacco products (including, but not limited to, cigarettes, pipes, 
cigars, chewing tobacco, nicotine patches, nicotine lozenges, nicotine gum, or vaping 
products) will be instructed that use of nicotine -containing products (including nicotine 
patches) will not be permitte d while they are in the clinical unit. 
5.3.3.  Activity   
Participant s will abstain from strenuous exercise for 48 hours  before each blood collection for 
clinical laboratory tests.  Partici pants may take part  in light recreational activities during the study 
(for example , watch ing television, read ing). 
5.4. Screen Failures   
A screen failure occurs  when a participant  who consent s to participate in the clinical study  is not 
subsequently enrolled  in the study .  
Individuals who do not meet the criteria for participation in this study (screen failure) may not  be 
rescreened.  
5.5. Criteria for Temporarily Delaying 
Enrollment/Randomization/Administration of Study Intervention of 
a Participant   
Not applicable.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 22 6. Study Intervention (s) and Concomitant Therapy   
Study intervention is defined as an y investigational intervention (s) or marketed product(s ) 
intended to be administered to /used by  a study participant according to the study protocol.   
6.1. Study Interventions Administer ed  
This study involves the comparison of rosuvastatin administered alone and rosuvastatin 
coadministered with selpercatinib.  
This table lists the interventions used in this clinical study.    
Intervention Name  Selpercatinib  Rosuvastatin  (Crestor ) 
Dose Formulation  Capsule  Tablet  
Dosage Level(s)  2 × 80-mg capsules  
(160-mg dose)  1 × 20-mg tablet  
(20-mg dose)  
Route of Administration  Oral Oral 
Dosing instructions  2 capsules taken on Day  5 1 tablet taken on Day  1 and 
Day 5 
 
Packaging and labeling  
Study interventions will be supplied by the sponsor or its designee in accordance with current 
Good Manufacturing Practice. Study interventions will be labeled as appropriate for country 
requirements.  
 
6.1.1.  Administration Details   
Rosuvastatin  will be administered orally with approximately 240  mL of room temperature water 
in the morning of  Day 1 (see Section  1.3) in a sitting position. When  rosuvastatin and 
selpercatinib are administered simultaneously  on Day  5, approximately  240 mL of room 
temperature water will be used. Selpercatinib should be administered at the same time as 
rosuvastatin.  If required to complete dosing, additional  water may be given in 50  mL aliquots 
and will be recorded in the source but will not be  considered as a protocol deviation.  
Participants will not be allowed to lie supine for 2  hours after dosing, unless clinically indicated 
or for study procedures.  
On Day  1, rosuvastatin will be administered alone after an overnight fast of at least 8  hours and 
participants will rem ain fasting for approximately 4  hours postdose . On Day  5, rosuvastatin and 
selpercatinib will be coadministered simultaneousl y after an overnight fast of at least 8  hours and 
participants will remain fasting for approximately 4  hours postdose . Water is per mitted ad 
libitum during the fasting period, except for 1 hour before and after dose administration.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 23 6.2. Preparation , Handling , Storage , and Accountability   
 The investigator or design ee must confirm appropriate storage conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention.  
 Only participants enrolled in the study may receive  study intervention . Only 
authorized study personnel  may supply , prepare,  or administer study intervention.  
 All study intervention must be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the labe led storage 
conditions with access limited to the investigator and authorized  study personnel . 
 The investigator  or authorized study personnel are  responsible for study intervention 
accountability, reconciliation, and record maintenance ( that is,  receipt, r econciliation, 
and final disposition records).  
 Note: In some cases, sites may destroy the material if, during the investigative site 
selection, the evaluator has verified and documented that the site has appropriate 
facilities and written procedures to dis pose of clinical materials.   
 Further guidance and information for the final disposition of unused study 
interventions are provided in the Pharmacy Manual.  
6.3. Assignment to Study Intervention   
This is a nonrandomized, open -label study.    
6.4. Blindin g  
Not applicable as this is an open -label study .  
6.5. Study Intervention Compliance   
Study intervention will be administered under medical supervision by the investigator or 
designee. The dose of study intervention and study participant identification will be confirmed 
prior to the time of dosing. The date and time of each dose administere d will be recorded in the 
source documents and will be provided to the sponsor as requested .   
Study site personnel will examine each participant’s mouth to ensure that the study intervention 
was ingested.  
6.6. Dose Modification   
Dose modification is not permitted in this study.  
6.7. Continued Access to Study Intervention after the End of the Study   
Not applicable.  
  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 24 6.8. Treatment of Overdose   
For this study, any dose of selpercatinib  greater than 160 mg or rosuvastatin greater than 20  mg 
within a 24-hour time period will be considered an overdose.  
Sponsor does not recommend specific treatment for an overdose . 
In the event of an overdose, the investigator should:  
● Contact the medical monitor immediately.  
● Closely monitor the participant for any AE/ seriou s adverse event ( SAE ) and 
laboratory abnormalities as medically appropriate . 
● Obtain a plasma sample for PK analysis if requested by the medical monitor 
(determined on a case -by-case basis).  
● Document the quantity of the excess dose as well as the durati on of the overdose 
in the case report form ( CRF ). 
6.9. Prior and Concomitant Therapy   
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or receives 
during the study must be recorded along with:  
● Reason for use  
● Dates of administration including start and end  dates  
● Dosage information including dose and frequency for concomitant therapy of 
special interest  
The medical monitor should be contacted if there are any questions regarding concomitant or 
prior therapy.  
Participants must abstain from taking prescripti on or nonprescription drugs (including vitamins 
and dietary or herbal supplements) within 14 days prior to dosing and until discharge from the 
study , unless, in the opinion of the investigator and sponsor, the medication will not interfere 
with the study.  
If concomitant use of strong and moderate CYP3A inhibitors or drugs known to prolong the QT 
interval cannot be avoided, monitor the QT interval with ECGs for approximately 4 hours 
following the dose of selpercatinib . 
Acetaminophen , at doses of 3 g/24 hours , is permitted for use at the discretion of the 
investigator for the treatment of headache, etc . Other concomitant medication may be considered 
on a case -by-case basis by the investigator in consultation with the  medical monitor if required . 
Contra ceptive medication is permitted as per the contraception requirements (Appendix  4 
[Section 10.4]), and hormone replacement therapy is also allowed.   
Other medication may be considered on a case -by-case basis by the investigator in consultation 
with the Lilly clinical pharmacologist (CP)/clinical research physician (CRP), or designee.  
Approved on 19 May 2023 GMT
CONFIDENTIAL Protocol Number J2G- MC-JZPB (a)
Page 257. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Participants discontinuing from the study prematurely for any reason must complete AEand 
follow-up procedures per Section 1.3of this protocol.
Discontinuation of the study as a whole are handled as part of Appendix 1 (Section ).
7.1. Discontinuation of Study Intervention
When necessary, a participant may be permanently discontinued from study intervention. If so, 
the participant will discontinue the study intervention (treatment), thereby discontinuing the 
treatment period, and will remain in the study to complete procedures for an early 
discontinuation visit and post-treatment follow-up, if applicable, as shown in the SoA. 
A participant should be permanently discontinued from the study if
● the participant becomes pregnant during the study,
● in the opinion of the investigator, the participant should permanently discontinue the 
study intervention for safety reasons
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 26 7.1.1.  Liver Chemistry Stopping Criteria   
Study drug will be discontinued for a participant if liver chemistry stopping criteria are  met. 
Phase 1 Liver Chemistry Stopping Algorithm  
The study drug should be discontinued if one or more of these conditions occur:  
Elevation  Exception  
ALT or AST >5 × ULN   
ALT or AST >3 × ULN and either TBL >2 × ULN or INR >1.5  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/ dL, 
then doubling of direct bilirubin should be 
used for drug interruption decisions rather 
than TBL>2x ULN.  
ALT or AST >3 × ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5 %)  
ALP >3 × ULN, when the source of increased ALP is the liver   
ALP >2.5 × ULN and TBL > 2 ×ULN  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL, 
then doubling of direct bilirubin should be 
used for drug interruption decisions rather 
than TBL>2 × ULN.  
ALP >2.5 × ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
Source: FDA Guidance for Industry: Drug -Induced Liver Injury: Premarketing Clinical Evaluation, July 2009  
and other consensus guidelines, with minor modifications  
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase;  
FDA = Food and Drug Administration; INR = international normalized ratio; TBL = total bilirubin;  ULN = upper 
limit of normal.  
 
Resuming study drug after elevated liver tests  
Resumption of the study drug can be considered only in consultation with the Lilly designated 
medical monitor and only if the liver test r esults return to baseline and if a self -limited non -drug 
etiology is identified. Otherwise, the study drug should be discontinued.  
 
7.1.2.  QTc Stopping Criteria   
If a clinically signific ant finding is identified (including, but not limited to changes from baseline 
QTcF ) after enrollment, the investigator or qualified designee will determine if the participant  
can continue on the study  intervention and if any change in participant  management is needed . 
This review of the ECG printed at the time of collection  must be documented . Any new 
clinically relevant finding should be reported as an AE. 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 27 7.2. Participant Discontinuation/ Withdrawal from the Study   
Discontinuation is expected to be uncommon.  
A participant  may withdraw from the study : 
● at any time at the participant’s  own request  for any reason or without providing 
any rea son 
● at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons  
● if enrolled in any other clinical study involving an investigational product , or 
enrolled in any other type of medical research judged not to be sci entifically or 
medically compatible with this study  
● if the participant , for any reason, requires treatment with a therapeutic agent that 
is prohibited by the protocol .  
At the time of discontinuing from the study, if possible,  the participant will complete  procedures 
for an early discontinuation visit , as shown in the SoA. If the participant has not already 
discontinued the study intervention, the participant will be permanently discontinued from the 
study intervention.  
If the participant  withdraws consent  for disclos ure of future information, the s ponsor may retain 
and continue to use any data collected before such a withdrawal of consent . If a participant  
withdraws from the study, the participant  may request destruction of any samples taken and not 
tested , and the investigator must document this in the site study records . 
7.3. Lost to Follow  up  
A participant will be considere d lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site. Site personnel or designee are 
expected to make diligent attempts to contact participants who fail to return for a scheduled v isit 
or were otherwise unable to be followed up by the site.   
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 28 8. Study Assessments and Procedures   
● Study procedures and their timing are summarized in the SoA  (Section 1.3).  
● Immediate  safety concerns  should be discussed with the s ponsor immediately 
upon occurrence or awareness to determine if the participant sh ould continue or 
discontinue study intervention . 
● Adherence to the study design requirements, including those specified in the SoA, 
is essential and required for study conduct.  
● All screening evaluations must be completed and reviewed to confirm that  
potential participant s meet all eligibility criteria. The investigator will maintain a 
screening log to record details of all participant s screened and to confirm 
eligibility or record reasons for sc reening failure, as applicable.   
● Appendix  2 (Section  10.2) lists the laboratory tests that will be performed for this 
study.  
● Appendix  2 (Section  10.2.1 ) provides a summary of the maximum number and 
volume of invasive samples, for all sampling, during the study.  
● Unless otherwise stated in subsections below, all samples collected for specifi ed 
laboratory tests will be destroyed within 60 days of receipt of confirmed test 
results. Certain samples may be retained for a longer period, if necessary, to 
comply with applicable laws, regulations, or laboratory certification standards.  
8.1. Efficacy Asses sments   
Efficacy is not evaluated in this study.   
8.2. Safety Assessments   
Planned time points for all safety assessments are provided in the SoA.  
8.2.1.  Physical Examinations   
● A complete physical examination will include, at a minimum, assessments of the 
cardiovascular, respiratory, gastrointestinal , dermatological , and neurological  
systems. Height and weight will also be measured and recorded . 
● A symptom -directed physical examination will be performed at other visits, as 
deemed necessary by the investigator.  
● Investigators should pa y special attention to clinical signs related to previous 
serious illnesses.  
8.2.2.  Vital Signs   
● For each  participant , vital signs measurements should be conducted according to 
the SoA  (Section  1.3). 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 29 ● Blood pressure and pulse rate should be measured after at least 5  minutes in the 
supine position . When possible, measurements of blood pressure and pulse rate 
should be performed at approximately the same time of day at each scheduled 
time point.  
● If orthostatic measurements are required, participants should be supine for at least 
5 minutes and stand for at least 3  minutes. Unsched uled orthostatic vital signs 
should be assessed, if possible, during any AE of dizziness or posture -induced 
symptoms.  
● Additional vital signs may be measured during each study period if warranted.  
● If the participant feels unable to stand, supine vital signs only will be recorded.  
8.2.3.  Electrocardiograms   
● For each participant, a single  12-lead digital ECG will be collected according to 
the SoA  (see Section  1.3). Electrocardiograms must be recorded before collecting 
any blood samples. Participants must be supine for approximately 5  to 10 minutes 
before  ECG collection and remain supine but awake during ECG collection. 
Electrocardiograms may be obtained at additional times, when deemed clinically 
necessary. All ECGs recorded should be stored at the investigational site.  
● Any clinically significant findi ngs from ECGs that result in a diagnosis and that 
occur after the participant receives the first dose of the investigational product, 
should be reported to Lilly, or its designee, as an AE via eCRF.  
● Electrocardiograms will be interpreted by a qualified p hysician (the investigator 
or qualified designee) as soon after the time of ECG collection as possible, and 
ideally while the participant is still present, to determine whether the participant 
meets entry criteria at the relevant visit(s) and for immediate  participant 
management, should any clinically relevant findings be identified.  
● If a clinically significant finding is identified (including, but not limited to, 
changes in QT/QTc interval from baseline) after enrollment, the investigator will 
determine if the participant can continue in the study. The investigator, or 
qualified designee, is responsible for determining if any change in participant 
management is needed  and must document his/her review of the ECG printed at 
the time of collection. Any new c linically relevant finding should be reported as 
an AE. 
8.2.4.  Clinical Safety Laboratory Tests   
● See Appendix 2 (Section  10.2) for the list of clinical laboratory tests to be 
performed and the So A for the timing and frequency.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 30 ● The investigator must review the laboratory results , document this review, and 
report any clinically relevant changes occurring during the study as an AE . The 
laboratory results must be retained with source documents unless a Source 
Documen t Agreement or comparable document cites an electronic location that 
accommodates the expected retention  duration. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, 
unless judged by the investigator to be more severe than expected for the 
participant's condition.  
● All laboratory tests with va lues considered clinically significantly abnormal 
during participation in the study after the last dose of study intervention should be 
repeated until the values return to normal or baseline or are no longer considered 
clinically significant by the investigator or medical monitor.  
○ If such values do not return to normal/baseline within a period of time judged 
reasonable by the investigator, the etiology should be identified  and the 
sponsor notified.  
○ All protocol -required laboratory assessments, as  defined in Appendix 2, must 
be conducted in accordance with the SoA , standard collection requirements , 
and laboratory manual . 
● If laboratory values from non -protocol specified laboratory assessments 
performed at an investigator -designated local laborator y require a change in 
participant management or are considered clinically significant by the investigator 
(for example , SAE or AE), then  report the information as an AE . 
● If a central vendor is used for the study, Lilly or its designee will provide the 
investigator with the results of laboratory tests analyzed by a central vendor.  
8.2.5.  Pregnancy Testing   
Where applicable, pregnancy tests will be performed as outlined in the SoA (see Se ction  1.3). 
8.2.6.  Safety Monitoring   
The Lilly CP or CRP , or designee will monitor safety data throughout the course of the study.  
Lilly will review SAEs within time frames mandated by company procedures. The Lilly CP or 
CRP will periodically review:  
 trends in safety data,  
 laboratory analytes, and  
 AEs.  
When appropriate, the Lilly CP or CRP will consult with the functionally independent Global 
Patient Safety therapeutic area physician or clinical research scientist.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 31 8.2.6.1.  Hepatic Safety   
Close hepatic monitoring  
Laboratory tests, including ALT, AST, alkaline phosphatase ( ALP ), total bilirubin ( TBL ), direct 
bilirubin, gamma -glutamyl  transferase, and creatine kinase, should be repeated within 
48 to 72 hours to confirm the abnormality and to determine if it is increasing or decreasing, if 
1 or more of th ese conditions occur:  
If a participant with baseline 
results of...  develops the following elevations:  
ALT or AST <1.5 × ULN  ALT or AST ≥3 × ULN  
ALP <1.5 × ULN  ALP ≥2 × ULN  
TBL <1.5 × ULN  TBL ≥2 × ULN (except for participants with Gilbert’s 
syndrome)  
  
ALT or AST ≥1.5 × ULN  ALT or AST ≥2 × baseline  
ALP ≥1.5 × ULN  ALP ≥2 × baseline  
TBL ≥1.5 × ULN  TBL ≥1.5 × baseline (except for participants with 
Gilbert’s syndrome)  
Abbreviations: ALP = alkaline phosphatase; ALT  = alanine aminotransferase; AST  = aspartate aminotransferase; 
TBL  = total bilirubin; ULN  = upper limit of normal.  
 
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation fo r 
possible causes of abnormal liver tests should be initiated by the investigator in consultation with 
the Lilly -designated medical monitor. At a minimum, this evaluation should include physical 
examination and a thorough medical history, including symptom s, recent illnesses (for example, 
heart failure, systemic infection, hypotension, or seizures), recent travel, history of concomitant 
medications (including over -the-counter), herbal and dietary supplements, history of alcohol 
drinking and other substance abuse.  
Initially, monitoring of symptoms and hepatic biochemical tests should be done at a frequency of 
1 to 3 times weekly, based on the participant’s clinical condition and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be lowe red to once every 1  to 2 weeks, if the 
participant’s clinical condition and laboratory results stabilize. Monitoring of ALT, AST, ALP, 
and TBL should continue until levels normalize or return to approximate baseline levels.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 32 Comprehensive hepatic evaluation  
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
1 or more of these conditions occur:  
If a participant with baseline 
results of...  develops the following elevations:  
ALT or AST <1.5 × ULN  ALT or AST ≥3 × ULN with hepatic signs/symptoms a, 
or ALT or AST ≥5 × ULN  
ALP <1.5 × ULN  ALP ≥3 × ULN  
TBL <1.5 × ULN  TBL ≥2 × ULN (except for participants with Gilbert’s 
syndrome)  
  
ALT or AST ≥1.5 × ULN  ALT or AST ≥2 × baseline with hepatic 
signs/symptoms a, or ALT or AST ≥3 × baseline  
ALP ≥1.5 × ULN  ALP ≥2 × baseline  
TBL ≥1.5 × ULN  TBL ≥2 × baseline (except for participants with Gilbert’s 
syndrome)  
Abbreviations: ALP = alkaline phosphatase; ALT  = alanine aminotransferase; AST  = aspartate aminotransferase; 
TBL  = total bilirubin; ULN  = upper limit of normal.  
a Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, 
or eosinophilia >5%.  
 
At a minimum, this evaluation should include physical examination and a thorough medical 
history, as outlined above, as well as tests for prothrombin time -international normalization ratio; 
tests for viral hepatitis  A, B, C, or E; tests for autoimmune hepatitis; and an abdominal imaging 
study (for example, ultrasound or computed tomography  scan).  
Based on the participant’s history and initial results, further testing should be considered in 
consultation with the Lilly -designated medical monitor, including tests for:  
 hepatitis D virus,  
 cytomegalovirus,  
 Epstein -Barr virus,  
 acetaminophen levels,  
 acetaminophen protein adducts,  
 urine toxicology screen,  
 Wilson’s disease,  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 33  blood alcohol levels,  
 urinary ethyl glucuronide, and  
 blood phosphatidylethanol.  
Based on the circumstances and the investigator’s assessment of the participant’s clinical 
condition, the investigator should consider referring the participant for a:  
 hepatologist or gastroenterologist consultation,  
 magnet ic resonance cholangiopancreatography,  
 endoscopic retrograde cholangiopancreatography,  
 cardiac echocardiogram, or  
 a liver biopsy.  
Additional hepatic data collection (hepatic safety CRF) in study participants who have 
abnormal liver tests during the study  
Additional hepatic safety data collection in hepatic safety CRFs should be performed in study 
participants who meet 1 or more of the following 5 conditions:  
1. Elevation of serum ALT to greater than or equal to 5 × ULN on 2  or more consecutive 
blood tests (if baseline ALT is less than 1.5 × ULN)  
o In participants with baseline ALT greater than or equal to 1.5 × ULN, the 
threshold is ALT greater than or equal to 3 × baseline on 2 or more consecutive 
tests 
2. Elevated TBL to greater than or equal to 2 × ULN (if baseline TBL is less than 
1.5× ULN) (except for cases of known Gilbert’s syndrome)  
o In participants with baseline TBL equal to or greater than 1.5 × ULN, the 
threshold should be TBL greater than or equal to 2 × baseline  
3. Elevation of serum ALP to greater than or equal to 2 × ULN on 2 or more consecutive 
blood tests (if baseline ALP is less than 1.5 × ULN)  
o In participants with baseline ALP greater than or equal to 1.5 × ULN, the 
threshold is ALP greater than or equal to 2 × baseline on 2 or more consecutive 
blood tests  
4. Hepatic event considered to be a SAE  
5. Discontinuation of study drug due to a hepatic event  
Note: the interval between the 2 consecutive blood tests should be at least 2 days.  
8.2.6.2.  Hypersensitivity Reactions  
Many drugs, including oral agents and biologic agents, carry the risk of systemic hypersensitivity 
reactions. If such a reaction occurs, additional data should be provided to the sponsor in the 
designated CRFs.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 34 Sites should have appropriately trained medical staff and  appropriate medical equipment 
available when study participants are receiving study intervention. It is recommended that 
participants who experience a systemic hypersensitivity reaction be treated per national and 
international guidelines.  
8.3. Adverse Events , Serious Adverse Events , and Product Complaints   
The definitions of the following events can be found in Appendix 3:  
 AEs 
 SAEs  
 Product complaints (PCs)  
These events will be reported by the participant . 
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet these definitions and remain responsible for following up events that 
are serious, considered related to th e study intervention or study procedures, or that caused the 
participant to discontinue the study  intervention  (see Sectio n 7). 
Care will be taken not to introduce bias when detecting events. Open -ended and non -leading 
verbal questioning of the participant is the preferred method to inquire about event occurrences.  
After the initial report, the investigator is required to proactively follow each part icipant at 
subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event is 
otherwise explained, or the participant is lost to follow -up (as defined in Section 7.3). For PCs, 
the investigator is responsible for ensuring that follow -up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality. Further information on 
follow -up proce dures is provided in Appendix  3, Section  10.3. 
Investigators and any qualified designees are responsible for monitoring the safety of participants 
who have entered this study and for alerting Lilly or its designee to any event that seems unusual, 
even if this event may be considered an unanticipated benefit to the participant.  
The investigator is responsible for the appropriate medical care of parti cipants during the study.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 35 8.3.1.  Timing and Mechanism for Collecting Events   
This table describes the timing, deadlines , and mechanism for collecting events.  
Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -up 
Method of 
Reporting  
Adverse Event  
AE Start of 
intervention  Participation 
in study has 
ended  As soon as possible 
upon site awareness  AE CRF  N/A 
Serious Adverse Event  
SAE and SAE updates 
– prior to start of study 
intervention and 
deemed reasonably 
possibly related to 
study procedures  Signing of 
the ICF Start of 
intervention  Within 24 hours of 
awareness  SAE paper form  SAE paper 
form  
SAE # and SAE 
updates  – after start of 
study intervention  Start of 
intervention  Participation 
in study has 
ended  Within 24 hours of 
awareness  SAE paper form  SAE paper 
form  
SAE*  – after 
participant’s study 
participation has 
ended and the 
investigator becomes 
aware  After 
participant’s 
study 
participation 
has ended  N/A Promptly  SAE paper form  N/A 
Pregnancy  
Pregnancy in female 
participants and 
female partners of 
male participants  After the 
start of 
study 
intervention  Discharge 
from the 
CRU  Within 24 hours (see 
Section 8.3.2 ) Pregnancy 
paper form  Pregnancy 
paper form  
Product Complaints  
PC associated with an 
SAE  or might have led 
to an SAE  Start of 
study 
intervention  End of study 
intervention  Within 24 hours of 
awareness  PC form  N/A 
PC not associated with 
an SAE  Start of 
study 
intervention  End of study 
intervention  Within 1 business day 
of awareness  PC form  N/A 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 36 Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -up 
Method of 
Reporting  
Updated PC 
information  — — As soon as  possible 
upon site awareness  Originally 
completed 
Product 
Complaint form 
with all changes 
signed and 
dated by the 
investigator  N/A 
PC (if investigator 
becomes aware)  Participation 
in study has 
ended  N/A Promptly  Product 
Complaint form   
Abbreviations: AE  = adverse event; ICF = informed consent form; N/A = not applicable; PC = product 
complaints; SAE = serious adverse event.  
* Serious adverse events  should not be reported unless the investigator deems them to be possibly related to study 
treatment  or study participation  
8.3.2.  Pregnancy   
Collection of pregnancy information  
Male participants with partners who become pregnant  
● The investigator will attempt to collect pregnancy information on any male 
participant’s female partner who becomes pregnant while the male participant is 
in this study. This applies only to male participants who receive study 
intervention . 
● After learnin g of a pregnancy in the female partner of a study participant, the 
investigator will  
o obtain a consent  to release information  from the pregnant female partner 
directly, and 
o within 24 hours after obtaining this consent will record pregnancy information 
on th e appropriate form and submit it to the sponsor.  
The female partner will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to 
the sponsor. Generally, the follow -up will be no lo nger than 6 to 8 weeks 
following the estimated delivery date. Any termination of the pregnancy will be 
reported regardless of gestational age,  fetal status (presence or absence of 
anomalies) or indication for the procedure.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 37 Female participants who become p regnant  
● The investigator will collect pregnancy information on any female participant 
who becomes pregnant while participating in this study. The initial information 
will be recorded on the appropriate form and submitted to the sponsor within 
24 hours of  learning of a participant's pregnancy.  
● The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and the neonate  
and the information will be forwarded to the spons or. Generally, follow -up will 
not be required for longer than 6 to 8 weeks beyond the estimated delivery date. 
Any termination of pregnancy will be reported, regardless of gestational age,  fetal 
status (presence or absence of anomalies) or indication for t he procedure.  
● While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE.  
● A spontaneous abortion (occurring at <20 weeks gestation al age) or still birth 
(occurring at ≥20 weeks gestational age) is always considered to be an SAE and 
will be reported as such.  
● Any post -study pregnancy related SAE considered reasonably related to the study 
intervention by the investigator will be repo rted to the sponsor as described in 
protocol Section  8.3.1 . While the investigator is not obligated to actively seek this 
information in former study participants, he or she may learn of an SAE through 
spontaneous reporting.  
● Any female participant w ho becomes pregnant while participating in the study 
will be withdrawn from the study . If the participant is discontinued from the 
study, follow the standard discontinuation process  and continue directly to the 
follow -up phase. The follow -up on the pregnan cy outcome should continue 
independent of intervention or study discontinuation . 
8.4. Pharmacokinetics   
● Venous blood sa mples of approximately  each will be collected for 
measurement of plasma  concentrations of selpercatinib , rosuvastatin , and 
coproporphyrin I  as specified in the SoA  (Section  1.3).  
● A maximum of  samples may be collected at additional time points during the 
study if warranted and agreed upon between the investigator and the sponsor. The 
timing of sampling  may be altered during the course of the study based on newly 
available data ( for example , to obtain data closer to the time of peak plasma 
concentrations) to ensure appropriate monitoring.  
● Instructions for the collection and handling of biological samp les will be provided 
by the sponsor. The actual date and time (24 -hour clock time) of each sample will 
be recorded.  
Approved on 19 May 2023 GMT
CCI
CCI
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 38 8.4.1.  Bioanalysis   
 Samples will be analyzed at a laboratory approved by the sponsor and stored at a facility 
designated by the sponsor.  
 Concentrations of selpercatinib and rosuvastatin will be assayed using a validated liquid 
chromatography with tandem mass spectrometry method.  
 Concentrations of coproporphyrin I will be as sayed using a validated liquid 
chromatography with tandem mass spectrometry method.  
 Bioanalytical samples collected to measure investigational product concentrations will be 
retained for a maximum of 1 year following the last participant visit for the stud y. During 
this time, samples remaining after the bioanalyses may be used for exploratory analyses 
such as metabolism work, protein binding, or bioanalytical method cross -validation  
8.5. Pharmacodynamics   
Pharmacodynamic parameters a re not evaluated in this study . 
8.6. Genetics   
A blood sample for DNA isolation will be collected from participants  at screening  to determine 
genetic polymorphisms for participants to meet eligibility criteria  prior to enrollment 
(Section  5.2 and Section  5.2.1 ).  
A separate blood sample will be collected for storage for potential pharmacogenetic analysis  as 
specified in the SoA (Section  1.3). 
See Appendix 5 (Section  10.5) for information regarding genetic research  and Appendix  5 
(Section  10.1.11 ) for details about  sample retention and c ustody .  
8.7. Biomarkers   
Clinical study data indicate that the endogenous coproporphyrin I can be used to detect in vivo 
inhibition of hepatic OATPs; therefore, coproporphyrin I will be explored in this study as 
potential mechanistic biomarkers of OATP function. This may aid in mechanistic understanding 
of selpercatinib  effect on OATPs v ersus BCRP.  
At the visits and times specified in the SoA, venous blood samples will be collected to determine 
the plasma concentrations of coproporphyrin I. The actual date and 24 -hour clock time of each 
sampling will be recorded. Refer to the  SoA (Section 1.3) for coproporphyrin I sampling 
time points.  
8.8. Immunogenicity Assessments   
Immunogenicity  is not evaluated in this study.  
8.9. Health Economic s  
This section is not applicable for this study.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 39 9. Statistical Considerations   
9.1. Statistical Hypothes es  
The primary objective will be to evaluate the effect of a single dose of sel percatinib on BCRP 
activity in healthy participants assess ed by considering  the true DDI ratio of the inhibitory effect 
of selpercatinib on the BCRP substrate rosuvas tatin 
([rosuvastatin  + selpercatinib ] / rosuvastatin).   
Approximately 28  participants will  be enrolled to ensure that at least 20  evaluable participants 
complete the stud y. A total of 20  evaluable participants will provide at least 90% coverage 
probability to ensure the half -width of the 90% confidence interval (CI) for the AUC ratio of 
rosuvas tatin falls within 25% of the true ratio ([rosuvastatin  + selpercatinib ] / rosuvastatin).   
9.2. Analyses  Sets  
The following populations are defined:  
Population  Description  
Entered  All participants who sign the ICF.  
Enrolled/ Safety  All participants who receive at least 1  dose of rosuvastatin.  
Pharmacokinetic  
(Evaluable)  All participants who receive at least 1  dose of rosuvastatin and 
have evaluable PK data.  
9.2.1.  Study Participant Disposition   
A detailed description of participant disposition will be provided at the end of the study.  
9.2.2.  Study Participant Characteristics   
The participant’s age, sex, weight, height, and other demographic characteristics will be 
recorded.  
9.3. Statistical Analyses   
Statistical analysis of this study will be the responsibility of the sponsor or its designee.  
Pharmacokinetic analyses will be conducted on data from all participants who receive at least 
1 dose of rosuvastatin  and have evaluable PK.  
Safety analyses will be conducted for all enrolled participants who received study intervention, 
whether or not they completed all protocol requirements.  
Additional exploratory analyses of the data will be conducted as deemed appropriate. Study 
results may be pooled with the results of other studies for safety and population PK analysis 
purposes to avoid issues with post -hoc analyses and incomplete disclosures of analyses.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 40 9.3.1.  General Considerations   
Hand ling of missing, unused, and spurious data are addressed prospectively in the overall 
statistical methods described in the protocol and /or in the statistical analysis plan , where 
appropriate. Adjustments to the planned analyses are described in the final clinical study report . 
9.3.2.  Primary Endpoint  Analysis : Pharmacokinetic Analyses   
All PK analyses will be made using the PK Population.  
9.3.2.1.  Pharmacokinetic Parameter Estimatio n  
Pharmacokinetic parameter estimates for rosuvastatin will be calculated by standard 
noncompartmental methods of analysis.  
The primary parameters for analysis will be maximum ob served drug concentration ( Cmax) and 
area under the concentration versus time curve from time zero to infinity (AUC 0-∞) of 
rosuvastatin. Other noncompartmental parameters, such as  t1/2, tmax, apparent clearance, 
apparent volume of distribution , and area under the concentration versus time curve from time 
zero to time t, where t is the last time point with a measurable concentration ( AUC [0-tlast]), will 
be reported.  
Blood samples collected for the PK of selpercatinib alone will be used to determine Cmax only to 
ensure sufficient  selpercatinib  exposure  in systemic circulation . 
9.3.2.2.  Pharmacokinetic Statistical Inference   
Pharmacokinetic parameters for rosuvastatin  alone  dosed  on Day 1 will be compared to PK 
parameters for rosuvastatin with single dose of selpercatinib dosed on Day 5.  
If a participant has an AE of vomiting that occurs at or before 2 times median t max of either 
rosuvastatin or selpercatinib,  the impacted period of this p articipant will be excluded from the 
PK summary statistics and statistical analysis . 
Log-transformed C max and AUC (0-∞) of rosuvastatin  will be evaluated in a linear mixed -effects 
model with fixed effects for treatment  and a random effect for  participant . The treatment 
differences will be back -transformed to present the ratios of geometric means and the 
corresponding 90% CIs. The test treatment is rosuvastatin  in the presence of selpercatinib , and 
reference treatment is rosuvastatin alone.  
The t max will be analyzed using a Wilcoxon signed rank test. Estimates of the median difference 
based on the observed medians, 90% CIs and p -values  from the Wilcoxon test will be calculated.  
9.3.3.  Secondary Endpoint  Analysis : Safety Analyses   
All safety analyses will be made using the Safety Population.  
The incidence of TEAEs and SAEs  will be reported separately  with respect to the dose date for 
selpercatinib (i.e., separate events  and perce ntages  will be reported  for AEs pre -selpercatinib  and 
post-selpercatinib ).   
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 41 9.3.3.1.  Clinical Evaluation of Safety   
All investigational product and protocol procedure AEs will be listed, a nd if the frequency of 
events allows, safety data will be summarized using descriptive methodology.  
The incidence of AEs for each treatment will be presented by severity and by association with 
investigational product as perceived by the investigator. Eac h AE will be classified by the most 
suitable term from the medical regulatory dictionary.  
The number of SAEs will be reported.  
9.3.3.2.  Statistical Evaluation of Safety   
Safety parameters that will be assessed include clinical  laboratory parameters  and vital signs. 
The parameters will be listed and summarized using standard descriptive statistics. Additional 
analysis will be performed if warranted upon review of the data.  
Additional details can be found in the statistical analysis plan.  
9.3.4.  Exploratory Endpoint Analysis   
9.3.4.1.  Analyses  for Coproporphyrin I   
The effect of a single dose of selpercatinib (Day  5) on plasma coproporphyrin I , a biomarker of 
OATP inhibition in healthy participants , will be explored .  
Plasma concentrations of coproporphyrin I will be characterized by standard noncompartmental 
methods  of analysis . Descriptive parameters, such as Cmax, tmax, and area under the 
concentration versus time curve from time zero to 24  hours (AUC 0-24), will be s ummarized, if 
feasible.  
Pharmacokinetic  parameters for coproporphyrin I  at the presence of rosuvastatin  dosed on Day 1 
will be compared to parameters for coproporphyrin I  with single dose of selpercatinib dosed on 
Day 5.  
If a participant has an AE of vomiting that occurs at or before 2 times median t max of 
selpercatinib , the impacted period of this participant will be excluded from the summary 
statistics and statistical analysis.  
9.3.4.2.  Statistical Evaluation   
Log-transformed C max and AUC 0-24 of coproporphyrin I will be evaluated in a linear 
mixed -effects model with fixed effects for treatment and a random effect for participant. The 
treatment differences will be back -transformed to p resent the ratios of geometric means and the 
corresponding 90%  CIs. The test treatment is coproporphyrin I  in the presence of selpercatinib, 
and reference treatment is coproporphyrin I alone.  
9.4. Interim Analys is  
No interim analyses are planned for this study. If an unplanned interim analysis is deemed 
necessary for reasons other than a safety concern, the protocol must be amended.   
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 42 9.5. Sample Size Determination   
Approximately 28 participants will be enrolled  to ensure that at least 2 0 evaluable participants 
complete the study . 
A total of 2 0 evaluable participants will provide at least 9 0% coverage probability to ensure the 
half-width of the 90% CI for the AUC ratio of  rosuvastatin falls within 25% of the true ratio  
([rosuvastatin  + selpercatinib ] / rosuvastatin ). Participants  are evaluable if adequate PK data are 
obtained sufficient for inclusion of the pa rticipant  in this analysis of AUC ratio. This sample size 
of at least 20  evaluable pa rticipants  (out of 2 8 treated ) assumes unknown selpercatinib  effect on 
rosuvastatin PK and intra -participant  coefficient of variation  of 33% for the PK parameter of 
interest for each treatment (precision method) based on internal data.   
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 43 10. Supporting Documentation and Operational Considerations   
10.1. Appendix 1: Regula tory, Ethical, and Study Oversight 
Considerations   
10.1.1.  Regulatory and Ethical Considerations   
● This study  will be conducted in accordance with the protocol and with the 
following:  
○ Consensus ethical principles derived from international guidelines including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences Internatio nal Ethical Guidelines  
○ Applicable International Council for Harmonisation (ICH) Good Clinical 
Practice (GCP) Guidelines  
○ Applicable laws and regulations  
● The protocol, protocol amendments, ICF, IB, and other relevant documents ( for 
example , advertisements) must be submitted to an IRB/IEC by the investigator 
and reviewed and approved by the IRB/IEC  before the study is initiated.  
● Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study de sign, except for changes 
necessary to eliminate an immediate hazard to study participants.  
● Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation except for changes necessary to eliminate an 
immediate hazard to study participants . 
● The investigator will be responsible for the following:  
○ Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedure s established by the IRB/IEC  
○ Notifying the IRB/IEC of SAEs  or other significant safety findings as required 
by IRB/IEC procedures  
○ Providing oversight of study conduct for participants under their responsibility 
and adherence to requirements of 21 C ode of Federal Regulations (C FR), ICH 
guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if 
applicable), and all other applicable local regulations  
○ Reporting to the sponsor or designee significant issues related to participant 
safety , participant rights, or data integrity  
● Investigator sites are compensated for participation in the study  as detailed in the 
clinical trial agreement . 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 44 10.1.2.  Financial Disclosure   
Investigators and sub -investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory author ities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3.  Informed Consent Process   
● The investigator or the investigator’s  representative will explain the nature of the 
study , including the risks and benefits,  to the potential participant and answer all  
quest ions regarding the study.  
● Potential p articipants must be informed that their participation is voluntary. 
Participants will be required to sign a statement of informed consent that meets 
the requirements of 21 CFR 50, local regulations, ICH guidelines, privacy , and 
data protection requirements, where applicable, and the I RB/IEC or study center.  
● The medical record must include a statement that written informed consent was 
obtained before the participant was enter ed in the study and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.  
● Participants must be reconsented to the most current version of the ICF(s) during 
their participation in the study.  
● A copy of the ICF(s) must be provided t o the participant  and is kept on file . 
10.1.4.  Data Protection   
● Participants will be assigned a unique identifier by the sponsor. Any participant 
records , datasets  or tissue samples  that are transferred to the sponsor will contain 
the identifier only; participant names or any information which would make the 
participant identi fiable will not be transferred.  
● The participant must be informed that the participant’s  personal study -related data 
will be used by the sponsor in accordance with local data protection law. The 
level of disclosure must also b e explained to the participant  who will be required 
to give consent for their data to be used as described in the informed consent . 
● The participant must be informed that their medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by 
the sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory 
authorities.  
● The sponsor has processes in place to ensure data protection, information security , 
and data integrity. These processes include appropriate contingency plan(s) for 
appropriate and timely response in the event of a data security breach.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 45 10.1.5.  Dissemination of Clinical St udy Data   
Communication of Suspended or Terminated Dosing  
If a decision is taken to suspend or terminate dosing in the trial due to safety findings, this 
decision will be communicated by Lilly to all investigators (for example, by phone and/or email) 
as soon as possible. It will be a requirement that investigators respond upon receipt to confirm 
that they understand the communication and have taken the appropriate action pr ior to further 
dosing any participants with study intervention. Any investigator not responding will be 
followed up by Lilly personnel prior to any further planned dosing. If a dose is planned 
imminently, Lilly personnel will immediately, and continually, use all efforts to reach 
investigators until contact is made and instructions verified.  
Reports  
The sponsor will disclose a summary of study information, including tabular study results, on 
publicly available websites where required by local law or regulat ion. 
The summary of results will be posted within the time frame specified by local law or regulation. 
If the study remains ongoing in some countries and a statistical analysis of an incomplete data set 
would result in analyses lacking scientific rigor (fo r example, underpowered) or compromise the 
integrity of the overall analyses (for example, trial not yet unblinded), the summary of results 
will be submitted within 1 year after the end of the study globally or as soon as available, 
whichever is earlier.  
Data 
The sponsor does not proactively share data from Phase 1 clinical trials. Requests for access to 
Phase 1 clinical trial data are evaluated on a case-by-case basis taking into consideration the 
ability to anonymize the data and the nature of the data collected.  
10.1.6.  Data Quality Assurance   
● All participant data relating to the study will be recorded on printed or electronic 
CRF s unless transmitted to the sponsor or designee electronically ( for example , 
laboratory data). The investigator is responsible for verifying that data entries are 
accurate and correct by physically or electronically signing the CRF.  
● The investigator must maintain accurate documentation (source data) that 
supports the information entered in  the CRF.  This might include laboratory tests, 
medical records, and clinical notes . 
● The investigator must review and confirm th at data entries are accurate and 
complete throughout the duration of the study, by physically or electronically 
signing the CRF, as instructed by the sponsor.  All completed CRFs must be 
signed prior to archival.  
● The investigator must permit study -related  monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct a ccess to source documents.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 46 ● Monitoring details describing strategy ( for example , risk -based initiatives in 
operations and quality such as risk management and mitiga tion strategies and 
analytical risk -based monitori ng), methods, responsibilities  and requirements, 
including handling of noncompliance issues and monitoring techniques are 
provided in the Monitoring Plan.  
● The sponsor or designee is responsible for the data management of this study 
includin g quality checking of the data.  
● The sponsor assumes accountability for actions delegated to other individuals ( for 
example , contract research organizations ). 
● The sponsor or designee will perform monitoring to confi rm that data transcribed 
into the CRF by authorized site personnel are accurate, complete, and verifiable 
from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the cu rrently 
approved protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements.  
● Records and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by the investigator for the time period outlined in the 
Clinical Trial Agreement (CTA)  unless local regulations or institutional policies 
require a longer retention period. No records may be destroyed during the 
retention period without the written approval of the sponsor. No records may be 
transferred to another location or party without written notification to the sponsor . 
● In addition, Sponsor  or its representatives will periodically check a sample of the 
participant data recorded against source documents at the study site. The study 
may be a udited by Sponsor  or its representatives, and/or regulatory agencies at 
any time. Investigators will be given notice before an audit occurs.  
Data Capture System  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeli ness 
of the data reported to the sponsor.   
An electronic data capture system (EDC) will be used in this study for the collection of CRF 
data. The investigator maintains a separate source for the data entered by the investigator or 
designee into the sponsor -provided EDC system. The investigator is responsible for the 
identification of any data to be considered source and for the confirmation that data reported are 
accurate and complete by signing the CRF . 
Data collected via the sponsor -provided data capture system will be  stored at third -party. The 
investigator will have continuous access to the data during the study and until decommissioning 
of the data capture system . Prior to decommissioning, the investigator will receive or access an 
archival copy of pert inent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system and reports/electronic transfers  will be provided to the 
investigator for review and retention. Data will subsequently be transferred from the central 
vendor to the Sponsor  data warehouse.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 47 Data from complaint forms submitted to the Sponsor  will be encoded and stored in the global 
product complaint management system.  
10.1.7.  Source Documents   
● Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s s ite. 
● Data reported  on or entered in the CRF and are transcribed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained. The investigator may need to request previous medical records 
or transfer records, depending on the study. Also, current medical records must be 
available.  
● Definition of what constitutes source data can be found in Section 10.1.7 . 
10.1.8.  Study and Site Start and Closure   
First Act of Rec ruitment  
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  
Study or Si te Termination  
The sponsor or sponsor’s designee reserves the right to terminate the study at any time for any 
reason at the sole discretion of the sponsor. Study site will be closed upon study completion. A 
study site is considered closed when all required documents and study supplies have been 
collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the i ntended termination.  
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to:  
For study termination:  
● Discontinuation of further study intervention development  
For site termination:  
● Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines  
● Inadequate recruitment (evaluated after a reasonable amount of time) of 
participants by the investigator  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as s pecified by the applicable 
regulatory requirements. The investigator shall promptly inform the participant  and should assure 
appropriate participant  therapy and/or follow -up. 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 48 10.1.9.  Publication Policy   
In accordance with the sponsor’s publication policy, the results of this study will be submitted 
for publication by a peer -reviewed journal if the results are deemed to be of significant medical 
importance.  
10.1.10.  Investigator Information   
Not applicable . 
10.1.11.  Sample Retention   
Sample retention enables use of new technologies, response to regulatory questions, and 
investigation of variable response that may not be observed until later in the development 
of selpercatinib  or after selpercatinib become(s) commercially available.  
Sample Type  Custodian  Retention Period After Last 
Patient Visit*  
Long -term storage samples  Sponsor or Designee  15 years  
Pharmacokinetic  Sponsor or Designee  1 year  
Genetics  Sponsor or Designee  15 years  
 
  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 49 10.2. Appendix 2: Clinical Laboratory Tests   
● The tests detailed in the table below will be performed by the local laboratory . 
● Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 5 of the protocol.  
● Additional tests may be performed at any time during the study as determined 
necessary by the investigator or required by local regulations.  
● Investigators must document their review of the laboratory safety results .  
  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 50  
Clinical Laboratory Tests  
Hematology  Clinical Chemistry  
Hematocrit  Sodium  
Hemoglobin  Potassium  
Erythrocyte count (RBC)  Calcium  
Mean cell volume  Phosphorus  
Mean cell hemoglobin  Glucose (random)  
Mean cell hemoglobin concentration  Creatine kinase  
Leukocytes (WBC)  Blood urea nitrogen (BUN)  
Platelets  Uric acid  
Differential WBC (absolute counts) of : Total protein  
Neutrophils  Albumin  
Lymphocytes  Total bilirubin  
Monocytes  Alkaline phosphatase (ALP)  
Eosinophils  Aspartate aminotransferase (AST)  
Basophils  Alanine aminotransferase (ALT)  
 Creatinine  
Urinalysis   
Specific gravity  Pregnancy test  
pH FSH (if applicable) b 
Protein  Ethanol testing c 
Glucose  Urine drug screen c 
Ketones   
Bilirubin  Serology  
Urobilinogen  Hepatitis B surface antigen b 
Leukocytes  Hepatitis C antibody b,d 
Blood  HIVb 
Nitrite   
Microscopic examination of sediment a  
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus.  
a Test only if dipstick result is abnormal.  
b Performed at screening only.  
c Urine drug screen and ethanol (urine or breath) level performed at screening and may be repeated prior to 
admission to the clinical research unit . 
d Participants with a positive hepatitis C antibody test result can have a confirmatory hepatitis C RNA test.  
 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 51 10.2.1.  Blood Sampling Summary   
This table summarizes the approximate number of venipunctures and blood volumes for  all 
blood sampling (screening, safety laboratories, and bioanalytical assays) during the  study.  
Protocol J2G -MC-JZPB Sampling Summary  
 
Purpose  Blood Volume per 
Sample (mL)  Number of Blood 
Samples  Total Volume 
(mL)  
Screening tests a 
Clinical laboratory tests a 
Rosuvastatin pharmacokinetic sb 
Selpercatinib pharmacokinetics b 
Coproporphyrin I pharmacokinetics b 
Pharmacogenetics  
Total  
Total for clinical purposes [rounded up to nearest 10 mL]  
a Additional samples may be drawn if needed for safety purposes.  
b Includes additional 3 samples, if required.  
 
  
Approved on 19 May 2023 GMT
CCI
CCI
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 52 10.3. Appendix 3: Adverse Events  and Serious Adverse Events : Definitions 
and Procedures for Recording, Evaluating, Follow -up, and 
Reporting   
AE Definition  
 An AE is any untoward medical occurrence in a participant administered a pharmaceutical 
product and  which does not necessarily have a causal relationship with the study 
intervention. An AE can therefore be any unfavourable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a medicinal (investigational) product, whether or not  related to 
the medicinal (investigational) product . 
 
Events Meeting the AE Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (for example, ECG, radiological scans, vital signs 
measu rements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator (that is, not related 
to progression of underlying disease).  
 Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
 New condition detected or diagnosed after study intervention administration even though 
it may have been present before the start of the study.  
 Signs, symptoms, or  the clinical sequelae of a suspected drug -drug interaction.  
 Medication error, misuse, or abuse of IMP, including signs, symptoms, or clinical 
sequelae.   
 The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be 
reported as AE or SAE if they fulfill the definition of an AE or SAE. Also, lack of 
efficacy or failure of expected pharmacological action also constitutes an AE or SAE.   
 
Events NOT  Meeting the AE Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.  
 The disease/disorder being studied or expected progression, signs, or symp toms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
 Medical or surgical procedure (for example, endoscopy, appendectomy): the condition 
that leads to the procedure is the AE.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 53  Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
10.3.1.  Definition of S AE  
An SAE is defined as any untoward medical occurrence that, at any dose, meets one or 
more of the criteria listed:  
 Results in death  
 Is life -threatening  
o The term life-threatenin g in the definition of serious  refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.  
 Requires inpatient hospitalizatio n or prolongation of existing hospitalization  
o In general, hospitalization signifies that the participant has been admitted to 
hospital or emergency ward (usually involving at least an overnight stay) for 
observation and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospitalization are AEs. If a complication prolongs hospitalization or fulfills any 
other serious criteria, the event is serious. When in doubt as to whether 
hospitalization occurred or was necessary, the AE should be considered serious.  
o Hospitalization for elective treatment of a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
 Results in persistent disability/incapacity  
o The te rm disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
o This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea,  
influenza, and accidental trauma (for example, sprained ankle) which may 
interfere with or prevent everyday life functions but do not constitute a substantial 
disruption.  
 Is a congenital anomaly/birth defect  
o Abnormal pregnancy outcomes (for example, spontaneous abortion, fetal death, 
stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.  
 Other situations:  
o Medical or scientific judgment should be exercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations such as important 
medical events that may not be immediately life -threatening or result in death or 
hospitalization but may jeopardize the participant or may require medical or 
surgical intervention to prevent one of the other outcomes listed in  the above 
definition. These events should usually be considered serious.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 54 o Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency or drug abuse.  
10.3.2.  Definition of Product Complaints   
Product Complaint  
 A product complaint is any written, electronic,  or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness  or 
performance of a study intervention . When the ability to use the study intervention safely 
is impacted, the following are a lso product complaints:  
o Deficiencies in labeling information, and  
o Use errors for device or drug -device combination products due to ergonomic 
design elements of the product.  
 Product complaints related to study interventions used in clinical trials are colle cted in 
order to ensure the safety of participants, monitor quality, and to facilitate process and 
product improvements.  
 Investigators will instruct participants to contact the site as soon as possible if he or she 
has a product complaint or problem with t he study intervention so that the situation can 
be assessed.  
 An event may meet the definition of both a product complaint and an AE/SAE. In such 
cases, it should be reported as both a product complaint and as an AE/SAE.  
10.3.3.  Recording and Follow -Up of AE and/or SAE  and Product Complaints   
AE, SAE , and Product Complaint Recording  
 When an AE/SAE /product complaint occurs, it is the responsibility of the investigator to 
review  all documentation (for example, hospital progress notes, laboratory reports, and 
diagnostics reports) related to the event.  
 The investigator will then record all relevant AE/ SAE/product complaint information in 
the participant’s medical records, in accord ance with the investigator’s normal clinical 
practice. AE/SAE information is reported on the appropriate CRF page and product 
complaint information is reported on the Product Complaint Form.  
 Note: An event may meet the definition of both a product complain t and an AE/SAE. In 
such cases, it should be reported as both a product complaint and as an AE/SAE.  
 It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to Sponsor or designee in lieu of completion of the CRF p age for AE/SAE and 
the Product Complaint Form for product complaints.  
 There may be instances when copies of medical records for certain cases are requested by 
Sponsor or designee. In this case, all participant identifiers, with the exception of the 
partici pant number, will be redacted on the copies of the medical records before 
submission to Sponsor or designee.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 55  The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible,  the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
 
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during the 
study and assign it to one of the following categories:   
 Mild: A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.  
 Moderate: A type of adverse event that is  usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research participant.  
 Severe: A type of adverse event that interrupts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic intervention. An 
AE that is assessed as severe should not be confused with a SAE. Severe is a category 
utilized for ratin g the intensity of an event; and both AEs and SAEs can be assessed as 
severe.  
An event is defined as ‘serious’ when it meets at least one of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.  
 
Assessment of Ca usality  
 The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE. The investigator will use clinical judgment to 
determine the relationship . 
 A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relat ionship of the event to study intervention 
administration will be considered and investigated.  
 The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products in their assessment.  
 For each AE/SAE, the i nvestigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
 There may be situations in which an SAE has occurred  and the investigator has minimal 
information to include in the initial repo rt to Sponsor or designee. However, it is very 
important that the investigator always make an assessment of causality for every event 
before the initial transmission of the SAE data to Sponsor or designee.  
 The investigator may change their opinion of causa lity in light of follow -up information 
and send a SAE follow -up report with the updated causality assessment.  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 56  The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of AEs and SAEs  
 The investigat or is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by Sponsor or 
designee to elucidate the nature and/or causality of the AE or SAE as fully as possible. 
This may inc lude additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
 If a participant dies during participation in the study or during a recognized follow -up 
period, the investigator will  provide Sponsor or designee with a copy of any postmortem 
findings including histopathology.  
10.3.4.  Reporting of SAEs   
SAE Reporting via an Electronic Data Collection Tool  
 The primary mechanism for reporting an SAE will be the electronic data collection tool.  
 If the electronic system is unavailable, then the site will use the SAE paper form (see next 
section) in order to report the event within 24 hours.  
 The site will enter the SAE dat a into the electronic system as soon as it becomes 
available.  
 After the study is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry of new data or changes to existing data.  
 If a site receives a report  of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electronic data collection tool has been taken 
off-line, then the site can report this information on a SAE paper form (see next section) 
or to the spons or or designee  by telephone.  
 Contacts for SAE reporting can be found in SAE Report .  
 
SAE Reporting via Paper Form  
 Facsimile transmission of the SAE paper form is the preferred method to transmit this 
information to the sponsor  or designee . 
 Initial notific ation via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.  
 Contacts for SAE reporting can be found in in SAE Report .  
 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 57 10.3.5.  Regulatory Reporting Requirements   
SAE Regulatory Reporting  
Prompt notification by the investigator to the sponsor of a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study 
intervention under clinical investigation are met.  
 The sponsor has a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a study intervention under 
clinical investigation. The sponsor will comply with country -specific regulatory 
requirements relating to safety reporting to the regulatory authority, Institutional 
Review Boards (IRB)/Independent Ethics Committees (IEC) , and investigators.  
 An investigator wh o receives an investigator safety report describing a SAE or other 
specific safety information (for example, summary or listing of SAEs) from the sponsor 
will review and then file it along with the Investigator’s Brochure and will notify the 
IRB/IEC, if ap propriate according to local requirements.  
  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 58 10.4. Appendix 4: Contraceptive and Barrier Guidance   
10.4.1.  Definitions   
Word/Phrase  Definition  
Women of childbearing  potential  
(WOCBP)  Adult females are considered WOCBP unless they are WNOCBP.  
Females less than 18 years of age are considered WOCBP if they have  
 had at least 1 cycle of menses, or  
 Tanner stage 4 breast development.  
Any amount of spotting should be considered menarche.  
Women not of childbearing 
potential  
(WNOCBP)  Females are considered WNOCBP if they  
 have a congenital anomaly such as Müllerian agenesis  
 are infertile due to surgical sterilization, or  
 are postmenopausal.  
Examples of surgical sterilization include total hysterectomy, bilateral 
salpingo -oophorectomy,  bilateral  salpingectomy,  or bilateral  oophorectomy.  
Postmenopausal state  The postmenopausal state is defined as a woman:  
 at any age at least 6 weeks  post-surgical  bilateral  
oophorectomy with or without hysterectomy, confirmed by 
operative note; or  
 aged at least 40 years and up to 55 years with an intact uterus, 
not on hormone  therapy a, who has had cessation of menses for at  
least 12  consecutive  months  without  an alternative  medical  cause,  
AND with a follicle -stimulating hormone >40 mIU/mL; or  
 55 years  or older  not on hormone  therapy,  who has had at least 
12 months of spontaneous amenorrhea, or  
 aged  at least 55 years  with a diagnosis  of menopause  prior  
to starting hormone replacement therapy.  
a Women should not be taking medications during amenorrhea such as oral contraceptives, hormones, 
gonadotropin -releasing hormone, anti -estrogens, selective estrogen receptor modulators (SERMs), or 
chemotherapy that could induce transient amenorrhea . 
10.4.2.  Contraception Guidance   
Male participants:  
 Are not required to adhere to contraceptive requirements.  
Female participants:  
 WNOCBP are not required to adhere to contraceptive requirements . This includes 
females who are:  
o Infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, 
bilateral salpingectomy, bilateral tubal occlusion, or bilateral tubal ligation),  
or congenital anomaly (for example, Müllerian agenesis)  
o Postmenopausal  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 59 WOCBP who are completely abstinent as their preferred and usual lifestyle, or in a same -sex 
relationship as their preferred and usual lifestyle:  
 
Must…  Must not…  
agree to either remain 
abstinent or stay in a same -
sex relationship  without 
sexual  relationships with 
males   use periodic abstinence methods  
o calendar  
o ovulation  
o symptothermal, or  
o post-ovulation  
 declare abstinence just for the duration of a trial, or  
 use the withdrawal method  
 
WOCBP who are NOT completely abstinent as their preferred and usual lifestyle, or NOT in a 
same -sex relationship as their preferred and usual lifestyle, must do the following:  
 
Topic  Condition  
Pregnancy testing  Have a negative serum  test result at screening followed by a negative  urine  result  
within  24 hours  prior  to treatment  exposure. See the protocol Schedule of 
Activities for subsequent pregnancy testing  requirements.  
Contraception  Agree  to use 2 forms  of effective contraception,  where  at least 1  form must be 
highly effective.  
These  forms  of contraception  must  be used during  the study  and after the study for 
at least 30 days after the last dose of the study intervention.  
 
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 60 10.4.3.  Contraception Methods   
The table illustrates examples of  highly effective, effective, and unacceptable methods of 
contraception.  
Methods  Examples  
Highly effective 
contraception (less than 1% 
failure rate)  female sterilization  
 combination oral contraceptive pill  
 progestin -only contraceptive pill (mini -pill) 
 implanted contraceptives  
 injectable contraceptives  
 contraceptive patch (only women <198 pounds or 90 kg)  
 total abstinence  
 vasectomy (if only sexual  partner)  
 fallopian tube implants (if confirmed by hysterosalpingogram)  
 combined contraceptive vaginal ring, or  
 intrauterine devices  
Effective contraception   male or female condoms with spermicide  
 diaphragms with spermicide or cervical sponges  
 barrier method with use of a spermicide  
o condom with spermicide  
o diaphragm with spermicide, or  
o female condom with spermicide  
Ineffective forms of 
contraception whether used 
alone or in any 
combination   spermicide alone  
 periodic abstinence  
 fertility awareness (calendar method, temperature method, cervical 
mucus, or symptothermal)  
 withdrawal  
 postcoital douche, or  
 lactational amenorrhea  
 
  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 61 10.5. Appendix  5: Genetics   
Use/Analysis of DNA  
● Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. Variable response to 
study intervention may be due to genetic determinants that impact drug 
absorption, distribution, m etabolism, and excretion; mechanism of action of the 
drug; disease etiology; and/or molecular subtype of the disease being treated. 
Therefore, where local regulations and IRB/IEC allow, a blood sample will be 
collected for DNA analysis from consenting part icipants.  
● DNA samples will be used for research related to selpercatinib  or cancer  and 
related diseases. They may also be used to develop tests/assays including 
diagnostic tests related to selpercatinib  and/or interventions of this drug class  and 
cancer . Genetic research may consist of the analysis of one or more candidate 
genes or the analysis of genetic markers throughout the genome or analysis of the 
entire genome  (as appropriate).  
● Additional analyses may be conducted if it is hypothesized that this may help 
further understand the clinical data.  
● The samples may be analyzed as part of a multi -study assessment of genetic 
factors involved in the response to selpercatinib  or study interventions of this 
class to understand study disease or related condit ions.  
● The results of genetic analyses may be reported in the clinical study report (CSR) 
or in a separate study summary.  
● The sponsor will store the blood and/or DNA samples in a secure storage space 
with adequate measures to protect confidentiality . 
● The samples will be retained while research on selpercatinib  or stu dy 
interventions of this class or indication  continues but no longer than 15 years or 
other period as per local requirements.  
  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 62 10.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments   
See Section 8.2.6.1  for guidance on appropriate test  selection.  
The Lilly -designated central laboratory should complete the analysis of all selected testing. The 
central laboratory will report results if a validated test or calculation is available.  
 
Hepatic Hematology Panel  Hepatic Clinical Chemistry Panel  
Hemoglobin  Total bilirubin  
Hematocrit  Direct bilirubin  
Erythrocytes (RBCs - red blood cells)  Alkaline phosphatase (ALP)  
Leukocytes (WBCs - white blood cells)  Alanine aminotransferase (ALT)  
Differential:  Aspartate aminotransferase (AST)  
Neutrophils, segmented  Gamma -glutamyl transferase (GGT)  
Lymphocytes  Creatine kinase (CK)  
Monocytes  Other Chemistry  
Basophils  Acetaminophen  
Eosinophils  Acetaminophen protein adducts  
Platelets  Alkaline phosphatase isoenzymes  
Cell morphology (RBC and WBC)  Ceruloplasmin  
Hepatic Coagulation Panel  Copper  
Prothrombin time, INR (PT -INR)  Ethyl alcohol (EtOH)  
Hepatitis A virus (HAV) testing:  Haptoglobin  
HAV total antibody  Immunoglobulin IgA (quantitative)  
HAV IgM antibody  Immunoglobulin IgG (quantitative)  
Hepatitis B virus (HBV) testing:  Immunoglobulin IgM (quantitative)  
Hepatitis B surface antigen (HBsAg)  Phosphatidylethanol (PEth)  
Hepatitis B surface antibody (anti -HBs)  Urine Chemistry  
Hepatitis B core total antibody (anti -HBc)  Drug screen  
Hepatitis B  core IgM antibody  Ethyl glucuronide (EtG)  
HBV DNA b Other Serology  
Hepatitis C virus (HCV) testing:  Anti-nuclear antibody (ANA)  
HCV antibody  Anti-smooth muscle antibody (ASMA) a 
HCV RNA b Anti-actin antibody c 
Hepatitis D virus (HDV) testing:  Epstein -Barr virus (EBV) testing:  
HDV antibody  EBV antibody  
Hepatitis E virus (HEV) testing:  EBV DNA b 
HEV IgG antibody  Cytomegalovirus (CMV) testing:  
HEV IgM antibody  CMV antibody  
HEV RNA b CMV DNA b 
Microbiology  Herpes simplex virus (HSV) testing:  
Culture:  HSV (Type 1 and 2) antibody  
Blood  HSV (Type 1 and 2) DNA b 
Urine  Liver kidney microsomal type 1 (LKM -1) antibody  
Abbreviations: Ig = immunoglobulin; INR = international normalized ratio; PT -INR = prothrombin 
time-international normalized ratio.  
a Not required if anti -actin antibody is tested.  
b Reflex/confirmation dependent on regulatory requirements, testing availability, or both.  
c Not required if anti -smooth muscle antibody (ASMA) is tested.   
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 63 10.7. Appendix 7: Provisions for Changes in Study Conduct During 
Exceptional Circumstances   
Not applicable.  
  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 64 10.8. Appendix 8: Abbreviations  and Definitions   
Term  Definition  
ab antibody  
abuse  Use of a study intervention for recreational purposes or to maintain an addiction or 
dependence  
AE adverse event  
ALP alkaline phosphatase  
ALT alanine aminotransferase  
AST aspartate aminotransferase  
AUC (0-∞) area under the concentration versus time curve from time zero to infinity  
AUC (0-24) area under the concentration versus time curve from time zero to  24 hours  
AUC (0-tlast) area under the concentration versus time curve from time zero to time t, where t is the 
last time point with a measurable concentration  
BCRP  breast cancer resistance protein  
CFR Code of Federal Regulations  
Cmax maximum observed drug concentration  
complaint  A complaint is any written, electronic, or oral communication that alleges deficien cies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
compliance  Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.  
COVID -19 coronavirus disease 2019  
CP clinical pharmacologist  
CRF case report form; a printed, optical, or electronic document designed to record all of the 
protocol -required information to be reported to the sponsor for each trial particip ant. 
CRP  clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician,  clinical research 
scientist, global safety physician or other medical officer.  
CRU  clinical r esearch unit  
DDI drug-drug interaction  
ECG  electrocardiogram  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 65 enroll  The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.  
enter  Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.  
FDA Food and Drug Administration  
GCP  good clinical practice  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
IB Investigator’s Brochure  
ICF informed  consent form  
ICH International Council for Harmonisation  
IEC independent ethics committee  
IMP Investigational Medicinal Product (see also “ investigational product”)  
A medicinal product which is being tested or used as a reference, including as a 
placebo, in a clinical trial.  
informed consent  A process by which a participant voluntarily confirms their willingness to participate in 
a particular study, after having been informed of all aspects of the study that are 
relevant to the participant’s deci sion to participate. Informed consent is documented by 
means of a written, signed and dated informed consent form . 
investigational 
product  A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, in cluding products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the au thorized form. See also “IMP.”  
OATP1B1  organic anion transporting polypeptide 1B1  
participant  Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a cont rol 
PC product complaint  
PK pharmacokinetics  
QTc corrected QT interval  
QTcB  QT corrected using Bazett’s formula  
QTcF  QT corrected using Fridericia’s formula  
SAE serious adverse event  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 66 screen  The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.  
SoA Schedule of Activities  
t1/2 terminal elimination half -life 
TBL total bilirubin  
TEAE  Treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.  
tmax time to maximum drug concentration  
ULN upper limit of normal  
  
Approved on 19 May 2023 GMT
CONFIDENTIAL  Protocol Number J2G-MC-JZPB (a) 
Page 67 11. References   
Crestor ® (rosuvastatin calcium) Tablets [Prescribing Information]. Wilmington, DE: 
AstraZeneca Pharmaceuticals LP; 2003. Revised May 2020. Accessed at 
https://www.azpicentral.com/crestor/crestor.pdf#page=1 on 19 December 2022 . 
Food and Drug Administration (FDA). Drug Development and Drug Interactions. Table of 
Substrates, Inhibitors  and Inducers. Accessed at https://www.fda.gov/drugs/drug -interactions -
labeling/drug -development -and-drug-interactions -table -substrates -inhibitors -and-inducers on 
02 December  2022 . 
Furukawa T, Wakabayashi K, Tamura A, et al. Major SNP (Q141K) variant of human ABC 
transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm Res. 
2009;26(2):469 -479. https://  doi: 10.1007/s11095 -008-9752 -7.  
International Transporter Consortium; Giacomini KM, Huang SM, Tweedie J, et al. Membrane 
transporters in drug development. Nat Rev Drug Discov . 2010;9(3):215 -236. 
Keskitalo JE, Zolk O, Fromm MF, et al. ABCG2 polymorphism markedly affects the 
pharmacokineti cs of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86(2):197 -203. 
https://  doi: 10.1038/clpt.2009.79 . 
Kim KA, Joo HJ, Park JY. ABCG2 polymorphisms, 34G>A and 421C>A in a Korean 
population: analysis and a comprehensive comparison with other popu lations. J Clin Pharm Ther. 
2010;35(6):705 -712. https://  doi: 10.1111/j.1365 -2710.2009.01127.x . 
Mendes P, Robles P G, Mathur S. Statin -induced rhabdomyolysis: a comprehensive review of 
case reports. Physiother Can. 2014;66(2):124 -132. https://  doi: 10.3138/ptc.2012 -65. 
Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically 
polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 
2011;63(1):157 -181. https://  doi: 10.1124/pr.110.0028 57. 
Wan Z, Wang G, Li T, et al. Marked alteration of rosuvastatin pharmacokinetics in healthy 
Chinese with ABCG2 34G>A and 421C>A homozygote or compound heterozygote. J 
Pharmacol Exp Ther. 2015;354(3):310 -315. https://  doi: 10.1124/jpet.115.225045 . 
Approved on 19 May 2023 GMT
Signature Page for VV-CLIN-116682 v1.0
Signature Page for VV-CLIN-116682 v1.0Approval
or
17-May-2023 19:51:35 GMT+0000
Approval
19-May-2023 14:04:04 GMT+0000
Approved on 19 May 2023 GMT
PPD
PPD